data_1kzt_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1kzt _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.72 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.421 ' O ' HG12 ' A' ' 37' ' ' ILE . 2.6 m-30 -67.03 124.99 90.22 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.269 -0.894 . . . . 0.0 110.367 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.467 ' HB3' HD23 ' A' ' 39' ' ' LEU . 48.5 Cg_endo -53.54 -19.14 13.0 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 124.085 1.571 . . . . 0.0 109.998 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.8 tpt180 -52.09 -31.49 30.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.324 -0.86 . . . . 0.0 110.403 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.572 HD13 ' CD1' ' A' ' 38' ' ' TRP . 1.1 pp -59.73 -156.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.076 -1.015 . . . . 0.0 110.312 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.572 ' CD1' HD13 ' A' ' 37' ' ' ILE . 19.9 p-90 -55.38 -18.61 7.01 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.133 -0.979 . . . . 0.0 110.554 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.548 ' N ' ' CE3' ' A' ' 38' ' ' TRP . 25.3 tp -68.03 -15.23 63.51 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.07 -1.019 . . . . 0.0 109.932 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.4 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 86.4 t60 -78.97 -40.07 32.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.268 -0.895 . . . . 0.0 110.044 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' A' ' 42' ' ' LEU . 25.8 p30 -67.74 -22.92 65.21 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.281 -0.887 . . . . 0.0 110.275 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 15.5 mt -69.52 -32.35 71.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 110.216 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -62.17 -31.73 80.03 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.67 -32.9 72.08 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.278 -1.131 . . . . 0.0 110.198 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -58.23 -43.71 87.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.261 -0.899 . . . . 0.0 110.364 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 78.7 mt -55.01 -43.41 69.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.18 -0.95 . . . . 0.0 110.321 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -51.25 -45.16 61.94 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.24 -0.912 . . . . 0.0 110.118 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.6 -36.99 84.52 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.242 -0.911 . . . . 0.0 110.029 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 70.5 m -62.46 -37.03 84.34 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.18 -0.95 . . . . 0.0 110.026 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -106.6 13.59 28.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.869 . . . . 0.0 110.176 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.14 -126.04 5.76 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.323 0 O-C-N 119.872 -1.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.744 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.402 ' H ' ' CD2' ' A' ' 40' ' ' HIS . 0.1 OUTLIER -130.95 79.75 70.88 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.252 -0.905 . . . . 0.0 110.056 . . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.15 -8.37 20.02 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.987 1.519 . . . . 0.0 110.489 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -64.53 -25.07 67.82 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.257 -0.902 . . . . 0.0 110.534 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.56 ' CG2' ' HB2' ' A' ' 40' ' ' HIS . 0.6 OUTLIER -121.82 121.26 63.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.185 -0.947 . . . . 0.0 110.314 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 65.5 p-90 -60.84 -42.4 97.7 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.408 -0.807 . . . . 0.0 110.87 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.599 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 14.8 tp -54.37 -21.95 10.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.931 -1.106 . . . . 0.0 109.73 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.56 ' HB2' ' CG2' ' A' ' 37' ' ' ILE . 80.8 t60 -75.63 -39.46 57.75 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.439 -0.788 . . . . 0.0 109.672 179.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -104.71 5.51 33.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.261 -0.899 . . . . 0.0 109.67 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.456 ' N ' ' O ' ' A' ' 38' ' ' TRP . 19.4 tp -63.11 -38.06 89.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.302 -0.874 . . . . 0.0 110.042 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -55.81 -36.71 66.8 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -63.92 -34.33 77.73 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.383 -1.069 . . . . 0.0 109.971 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -58.34 -46.13 86.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.29 -0.881 . . . . 0.0 110.218 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.48 HG22 ' CE2' ' A' ' 50' ' ' TYR . 17.3 mm -56.49 -43.93 79.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.282 -0.886 . . . . 0.0 110.144 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.495 ' O ' ' N ' ' A' ' 51' ' ' GLY . 66.2 t80 -45.58 -46.49 14.26 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.148 -0.97 . . . . 0.0 109.735 179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -61.46 -37.51 83.85 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.417 -0.802 . . . . 0.0 110.038 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 64.4 m -68.59 -32.08 71.73 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.185 -0.947 . . . . 0.0 110.01 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.48 ' CE2' HG22 ' A' ' 46' ' ' ILE . 96.5 m-85 -111.79 15.72 20.77 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.357 -0.839 . . . . 0.0 110.093 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 49.22 47.55 33.89 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.323 0 O-C-N 119.877 -1.955 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.756 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.427 ' O ' HG12 ' A' ' 37' ' ' ILE . 0.3 OUTLIER -123.96 75.27 57.81 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.17 . . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.46 ' O ' ' HB2' ' A' ' 40' ' ' HIS . 49.1 Cg_endo -59.73 -16.68 38.6 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 124.015 1.534 . . . . 0.0 110.346 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -56.63 -30.27 63.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.37 -0.831 . . . . 0.0 110.495 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.59 HD13 ' CG ' ' A' ' 38' ' ' TRP . 1.1 pp -58.68 -162.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.192 -0.943 . . . . 0.0 110.492 -179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.59 ' CG ' HD13 ' A' ' 37' ' ' ILE . 24.0 p-90 -53.85 -16.68 1.9 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.169 -0.957 . . . . 0.0 110.388 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.569 HD12 ' CZ3' ' A' ' 38' ' ' TRP . 16.5 tp -66.99 -26.53 66.84 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.999 -1.063 . . . . 0.0 109.325 179.24 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.46 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 86.4 t60 -60.85 -31.6 71.04 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.409 -0.807 . . . . 0.0 109.691 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.534 ' ND2' ' O ' ' A' ' 38' ' ' TRP . 18.2 p30 -95.64 -12.89 24.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.4 -0.813 . . . . 0.0 109.736 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.43 ' HB2' ' HA ' ' A' ' 39' ' ' LEU . 27.9 tp -45.17 -43.21 9.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.394 -0.816 . . . . 0.0 110.148 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -48.21 -31.19 8.4 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.416 ' HB2' ' O ' ' A' ' 41' ' ' ASN . 94.5 mt-30 -59.48 -34.98 73.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.367 -1.078 . . . . 0.0 109.925 179.818 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -51.48 -44.53 62.49 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.879 . . . . 0.0 109.915 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.51 HG21 ' CE2' ' A' ' 50' ' ' TYR . 21.0 mm -55.13 -45.73 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.939 . . . . 0.0 109.999 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.453 ' O ' ' N ' ' A' ' 51' ' ' GLY . 65.6 t80 -50.29 -46.33 55.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.267 -0.896 . . . . 0.0 109.838 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -68.23 -35.7 78.34 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.378 -0.826 . . . . 0.0 109.904 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 51.5 m -66.3 -36.18 82.3 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.256 -0.902 . . . . 0.0 109.964 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.51 ' CE2' HG21 ' A' ' 46' ' ' ILE . 90.7 m-85 -111.8 14.23 21.05 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.318 -0.864 . . . . 0.0 110.098 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -71.36 132.26 20.61 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.291 0 O-C-N 119.895 -1.944 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.705 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.512 ' HB2' ' CD2' ' A' ' 40' ' ' HIS . 0.4 OUTLIER -124.31 82.57 57.65 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 110.2 . . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.82 -6.58 18.36 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 124.041 1.548 . . . . 0.0 110.138 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 63.0 mtt180 -61.27 -30.89 70.75 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.292 -0.88 . . . . 0.0 110.476 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.554 ' CG2' ' HB2' ' A' ' 40' ' ' HIS . 0.7 OUTLIER -124.14 125.59 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.055 -1.028 . . . . 0.0 110.846 -179.611 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.549 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 67.8 p-90 -61.13 -45.06 96.2 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.472 -0.767 . . . . 0.0 110.753 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.549 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 8.5 tt -50.26 -27.22 5.69 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.01 -1.056 . . . . 0.0 109.628 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.554 ' HB2' ' CG2' ' A' ' 37' ' ' ILE . 82.0 t60 -70.72 -39.37 73.42 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.451 -0.781 . . . . 0.0 109.557 179.466 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 14.2 p30 -105.17 10.25 33.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.416 -0.802 . . . . 0.0 109.744 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.429 ' N ' ' O ' ' A' ' 38' ' ' TRP . 24.3 tp -60.78 -35.52 76.65 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.37 -0.831 . . . . 0.0 110.23 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -61.46 -33.76 85.91 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -59.15 -38.41 79.63 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.184 -1.186 . . . . 0.0 110.072 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -56.72 -35.78 68.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.388 -0.82 . . . . 0.0 110.302 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 94.5 mt -61.72 -40.21 86.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.118 -0.989 . . . . 0.0 110.371 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.411 ' O ' ' N ' ' A' ' 51' ' ' GLY . 75.5 t80 -54.27 -46.92 72.79 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.262 -0.899 . . . . 0.0 110.26 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -61.49 -38.06 85.95 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.177 -0.952 . . . . 0.0 110.124 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 54.2 m -61.36 -38.39 86.79 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.321 -0.862 . . . . 0.0 110.141 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -107.61 11.4 28.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.234 -0.916 . . . . 0.0 110.241 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 59.86 -121.22 25.94 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.353 0 O-C-N 119.783 -2.01 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.717 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.578 ' CE2' ' HD2' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -125.12 79.29 65.9 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.237 -0.914 . . . . 0.0 110.219 . . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.03 -6.87 18.19 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.974 1.513 . . . . 0.0 110.224 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.578 ' HD2' ' CE2' ' A' ' 34' ' ' PHE . 95.0 mtt180 -61.14 -32.49 72.2 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.265 -0.897 . . . . 0.0 110.345 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.549 ' CG2' ' HB2' ' A' ' 40' ' ' HIS . 0.5 OUTLIER -122.8 124.32 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.223 -0.923 . . . . 0.0 110.308 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.625 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 63.5 p-90 -60.96 -41.78 97.0 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.364 -0.835 . . . . 0.0 110.989 -179.502 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.625 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 15.6 tp -54.1 -24.19 16.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.946 -1.096 . . . . 0.0 109.493 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.549 ' HB2' ' CG2' ' A' ' 37' ' ' ILE . 80.0 t60 -72.27 -47.09 52.77 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.575 -0.703 . . . . 0.0 109.687 179.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -99.83 8.09 44.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.326 -0.859 . . . . 0.0 109.833 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.491 ' N ' ' O ' ' A' ' 38' ' ' TRP . 31.0 tp -54.36 -40.11 67.8 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.376 -0.827 . . . . 0.0 110.01 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -53.61 -37.58 56.82 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.069 -1.612 . . . . 0.0 109.069 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -61.8 -34.48 75.98 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 0.0 109.974 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -54.5 -43.57 71.95 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.235 -0.916 . . . . 0.0 109.888 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 mm -61.16 -37.96 78.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.9 . . . . 0.0 109.974 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 51' ' ' GLY . 64.4 t80 -46.88 -47.85 21.26 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.153 -0.967 . . . . 0.0 109.761 179.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -64.4 -37.8 88.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.361 -0.837 . . . . 0.0 109.978 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 58.9 m -63.76 -35.02 79.2 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.233 -0.917 . . . . 0.0 110.103 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -110.9 14.54 22.08 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.345 -0.847 . . . . 0.0 110.091 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 59.54 -160.59 18.11 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.339 0 O-C-N 119.849 -1.971 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.726 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -122.32 80.55 45.27 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.247 -0.908 . . . . 0.0 110.097 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -63.7 -16.67 56.1 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 124.005 1.529 . . . . 0.0 110.354 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 37.1 ttt180 -58.33 -35.16 71.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.357 -0.839 . . . . 0.0 110.294 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 1.5 pp -71.53 -3.01 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.233 -0.917 . . . . 0.0 110.396 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.515 ' O ' ' HB2' ' A' ' 39' ' ' LEU . 4.0 m95 -104.91 159.44 15.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.238 -0.914 . . . . 0.0 110.173 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.515 ' HB2' ' O ' ' A' ' 38' ' ' TRP . 17.6 mt 69.11 -50.72 0.6 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.459 -0.776 . . . . 0.0 110.999 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -61.7 -45.3 94.55 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.967 -1.083 . . . . 0.0 110.361 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -71.45 -33.25 69.19 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.242 -0.911 . . . . 0.0 110.418 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 56.3 mt -69.67 -25.17 63.77 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.265 -0.897 . . . . 0.0 109.992 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -60.18 -31.6 73.74 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -60.27 -35.26 75.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.233 -1.157 . . . . 0.0 109.993 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -52.94 -39.29 62.76 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.313 -0.867 . . . . 0.0 109.948 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.625 ' CG2' ' CE1' ' A' ' 50' ' ' TYR . 91.1 mt -59.01 -46.77 91.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.234 -0.916 . . . . 0.0 110.014 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.415 ' C ' ' O ' ' A' ' 46' ' ' ILE . 75.9 t80 -42.53 -52.16 4.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.436 -0.79 . . . . 0.0 109.797 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -59.83 -43.88 94.34 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.402 ' O ' ' HB3' ' A' ' 50' ' ' TYR . 48.1 m -61.37 -40.02 92.79 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.359 -0.838 . . . . 0.0 109.601 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.625 ' CE1' ' CG2' ' A' ' 46' ' ' ILE . 29.5 p90 -174.87 98.94 0.08 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.383 -0.823 . . . . 0.0 110.085 179.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.5 103.99 2.23 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.352 0 O-C-N 119.874 -1.956 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.731 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.602 ' HB2' ' CD2' ' A' ' 40' ' ' HIS . 22.5 m-85 -127.38 80.02 72.39 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.238 -0.914 . . . . 0.0 110.164 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -66.08 -8.12 19.17 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 O-C-N 123.956 1.503 . . . . 0.0 110.38 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 82.2 mtm180 -66.1 -26.34 67.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.267 -0.896 . . . . 0.0 110.624 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.546 ' CG2' ' HB2' ' A' ' 40' ' ' HIS . 0.3 OUTLIER -123.9 116.76 48.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.052 -1.03 . . . . 0.0 110.699 -179.532 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.654 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 55.3 p-90 -56.47 -41.07 75.94 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.432 -0.792 . . . . 0.0 110.733 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.654 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 0.7 OUTLIER -61.82 -12.75 18.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.18 -0.95 . . . . 0.0 110.757 -179.246 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.602 ' CD2' ' HB2' ' A' ' 34' ' ' PHE . 82.4 t60 -75.66 -24.75 56.39 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.049 -1.032 . . . . 0.0 109.942 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.529 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 7.2 m-80 -78.47 -17.73 55.87 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.296 -0.877 . . . . 0.0 109.08 179.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.449 HD13 ' HA ' ' A' ' 39' ' ' LEU . 9.2 mp -72.57 -32.92 66.4 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.244 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.467 ' O ' ' HB ' ' A' ' 46' ' ' ILE . . . -56.3 -42.42 88.72 Favored Glycine 0 N--CA 1.487 2.082 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 179.394 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -49.88 -40.07 41.52 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -1.141 . . . . 0.0 109.552 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 82.9 t60 -53.51 -35.39 60.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.232 -0.918 . . . . 0.0 109.452 179.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.473 ' O ' ' HB ' ' A' ' 49' ' ' THR . 95.6 mt -62.83 -43.45 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.337 -0.852 . . . . 0.0 109.355 179.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.568 ' HA ' ' CE1' ' A' ' 50' ' ' TYR . 71.5 t80 -43.18 -46.89 6.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.37 -0.831 . . . . 0.0 109.558 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -66.21 -30.59 71.08 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.337 -0.852 . . . . 0.0 109.796 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.473 ' HB ' ' O ' ' A' ' 46' ' ' ILE . 88.3 m -63.19 -45.54 91.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.25 -0.906 . . . . 0.0 109.886 179.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.568 ' CE1' ' HA ' ' A' ' 47' ' ' TYR . 41.8 p90 -116.99 25.87 10.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.279 -0.888 . . . . 0.0 110.132 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 55.97 -165.18 4.41 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.324 0 O-C-N 119.857 -1.966 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.769 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.553 ' HB2' ' CD2' ' A' ' 40' ' ' HIS . 8.4 m-85 -122.8 84.2 49.55 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.295 -0.878 . . . . 0.0 110.216 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -66.66 -8.39 20.99 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.989 1.521 . . . . 0.0 110.183 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 54.2 mtt85 -58.9 -33.57 70.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.428 -0.795 . . . . 0.0 110.857 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.555 ' CG2' ' HB2' ' A' ' 40' ' ' HIS . 0.2 OUTLIER -127.01 114.12 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.014 -1.054 . . . . 0.0 110.74 -179.45 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.652 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 41.6 p-90 -48.99 -38.71 24.07 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.573 -0.704 . . . . 0.0 110.576 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.652 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 9.2 tt -58.91 -27.9 65.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.257 -0.902 . . . . 0.0 110.08 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.555 ' HB2' ' CG2' ' A' ' 37' ' ' ILE . 54.7 t-80 -65.19 -35.54 81.38 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.328 -0.858 . . . . 0.0 110.115 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -79.4 -17.11 55.05 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.137 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 18.2 tp -74.39 -24.51 59.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.484 -0.76 . . . . 0.0 109.569 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -69.32 -29.43 71.87 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.04 -1.624 . . . . 0.0 109.04 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -58.63 -30.52 67.34 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.413 -1.051 . . . . 0.0 109.795 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -60.32 -38.66 84.41 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.407 -0.808 . . . . 0.0 110.373 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 22.9 mm -62.14 -37.2 77.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.123 -0.985 . . . . 0.0 110.306 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.474 ' O ' ' N ' ' A' ' 51' ' ' GLY . 75.0 t80 -54.15 -46.74 72.35 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.188 -0.945 . . . . 0.0 110.171 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -66.45 -38.01 86.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.205 -0.934 . . . . 0.0 110.39 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.9 m -65.21 -38.82 91.64 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.177 -0.952 . . . . 0.0 110.227 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -111.27 17.62 20.06 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.279 -0.888 . . . . 0.0 110.135 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -127.6 -108.54 1.49 Allowed Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.337 0 O-C-N 119.903 -1.939 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.759 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.463 ' O ' HG22 ' A' ' 37' ' ' ILE . 2.4 m-85 -124.7 79.23 63.35 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.26 -0.9 . . . . 0.0 110.156 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -55.71 -21.51 32.39 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.934 1.492 . . . . 0.0 110.468 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.459 ' O ' ' HB3' ' A' ' 40' ' ' HIS . 63.3 mtt180 -56.99 -39.74 75.26 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.207 -0.933 . . . . 0.0 110.484 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.527 HD12 HG21 ' A' ' 37' ' ' ILE . 0.0 OUTLIER -57.28 -28.55 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.22 -0.925 . . . . 0.0 110.218 -179.753 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.542 ' O ' ' HB2' ' A' ' 39' ' ' LEU . 17.3 m95 -98.29 146.24 25.86 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.172 -0.955 . . . . 0.0 110.838 -179.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.542 ' HB2' ' O ' ' A' ' 38' ' ' TRP . 28.6 mt 72.49 -44.72 0.6 Allowed 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.85 -0.531 . . . . 0.0 111.171 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.459 ' HB3' ' O ' ' A' ' 36' ' ' ARG . 58.1 t-80 -58.96 -40.44 84.73 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.677 -1.264 . . . . 0.0 110.207 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.463 ' HB2' ' OE1' ' A' ' 44' ' ' GLN . 47.9 p-10 -123.49 14.35 9.53 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.179 -0.951 . . . . 0.0 110.189 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.444 HD23 HD23 ' A' ' 39' ' ' LEU . 13.6 tp -59.83 -29.66 68.41 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.25 -0.906 . . . . 0.0 110.337 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -60.55 -26.74 64.97 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.463 ' OE1' ' HB2' ' A' ' 41' ' ' ASN . 94.2 mt-30 -71.25 -22.95 61.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.314 -1.11 . . . . 0.0 110.231 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -66.26 -46.09 78.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.324 -0.86 . . . . 0.0 110.563 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.45 ' O ' ' N ' ' A' ' 50' ' ' TYR . 17.8 pt -76.97 -10.61 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.21 -0.932 . . . . 0.0 110.539 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.505 ' C ' ' CD1' ' A' ' 47' ' ' TYR . 6.8 t80 -62.45 -49.24 76.24 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.14 -0.975 . . . . 0.0 110.22 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -56.82 -33.9 67.19 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.149 -0.969 . . . . 0.0 110.359 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 69.9 m -101.72 -73.52 0.65 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.328 -0.858 . . . . 0.0 110.707 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.45 ' N ' ' O ' ' A' ' 46' ' ' ILE . 93.1 m-85 -65.22 -33.66 76.53 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.271 -0.893 . . . . 0.0 110.454 -179.724 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 47' ' ' TYR . . . 77.95 41.13 19.26 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.317 0 O-C-N 119.858 -1.966 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.723 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.581 ' HB2' ' CD2' ' A' ' 40' ' ' HIS . 1.6 m-85 -122.77 83.2 49.13 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.314 -0.866 . . . . 0.0 110.201 . . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -71.19 -4.46 14.96 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.021 1.537 . . . . 0.0 110.128 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.448 ' CZ ' ' CE2' ' A' ' 34' ' ' PHE . 57.0 mtm180 -66.7 -26.95 67.27 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.304 -0.872 . . . . 0.0 110.582 -179.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.548 ' CG2' ' HB2' ' A' ' 40' ' ' HIS . 0.5 OUTLIER -122.97 119.39 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.035 -1.041 . . . . 0.0 110.757 -179.697 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.643 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 54.0 p-90 -56.99 -42.43 80.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.437 -0.79 . . . . 0.0 110.561 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.643 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 16.8 tp -51.62 -29.5 17.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.072 -1.017 . . . . 0.0 109.367 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.581 ' CD2' ' HB2' ' A' ' 34' ' ' PHE . 70.1 t60 -75.18 -44.22 47.82 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.519 -0.738 . . . . 0.0 109.186 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -79.82 -11.32 59.83 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.345 -0.847 . . . . 0.0 109.316 179.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.448 HD22 ' CZ3' ' A' ' 38' ' ' TRP . 18.9 tp -75.01 -28.11 60.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.419 -0.801 . . . . 0.0 109.801 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -65.14 -31.7 81.58 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -60.72 -35.59 76.73 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.471 -1.017 . . . . 0.0 109.408 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -59.26 -43.19 92.5 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.393 -0.817 . . . . 0.0 109.742 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 87.2 mt -54.74 -47.3 74.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.316 -0.865 . . . . 0.0 110.079 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 71.0 t80 -46.37 -43.88 16.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.237 -0.914 . . . . 0.0 110.077 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 74.7 mm-40 -64.13 -38.16 90.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.332 -0.855 . . . . 0.0 110.073 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 84.8 m -61.02 -49.09 78.8 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.254 -0.904 . . . . 0.0 110.245 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.476 ' O ' ' N ' ' A' ' 52' ' ' NH2 . 68.4 m-85 -74.54 -22.81 58.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 110.106 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 62.8 -75.59 0.03 OUTLIER Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . 0.476 ' N ' ' O ' ' A' ' 50' ' ' TYR . . . . . . . . 0 C--N 1.306 -1.32 0 O-C-N 119.919 -1.93 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.74 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.51 ' O ' ' CG1' ' A' ' 37' ' ' ILE . 20.2 m-85 -126.12 72.14 70.59 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.199 -0.938 . . . . 0.0 110.312 . . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.544 ' CB ' HD21 ' A' ' 39' ' ' LEU . 46.2 Cg_endo -51.21 -19.85 6.93 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 O-C-N 124.01 1.531 . . . . 0.0 110.436 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.405 ' O ' ' O ' ' A' ' 37' ' ' ILE . 81.7 mtt-85 -61.91 -26.83 68.4 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.207 -0.933 . . . . 0.0 110.464 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.6 HD13 ' CD1' ' A' ' 38' ' ' TRP . 1.4 pp -60.61 -151.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.139 -0.976 . . . . 0.0 110.538 -179.405 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.6 ' CD1' HD13 ' A' ' 37' ' ' ILE . 12.7 p-90 -57.29 -22.99 45.54 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.917 -1.114 . . . . 0.0 110.932 -178.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.573 ' HA ' ' CE3' ' A' ' 38' ' ' TRP . 18.8 tp -54.91 -28.87 54.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.804 -1.185 . . . . 0.0 108.632 179.081 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -62.85 -27.52 69.4 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 178.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.463 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 8.1 m-20 -58.26 -45.72 87.32 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.386 -0.821 . . . . 0.0 109.271 179.207 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 46.5 mt -56.37 -40.33 74.38 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.424 -0.798 . . . . 0.0 109.541 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -52.29 -27.97 25.84 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.463 ' HB2' ' O ' ' A' ' 41' ' ' ASN . 95.3 mt-30 -59.1 -36.2 74.73 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.256 -1.143 . . . . 0.0 110.112 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -55.08 -43.41 73.91 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.275 -0.891 . . . . 0.0 110.448 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.442 ' HA ' HG23 ' A' ' 49' ' ' THR . 93.8 mt -60.51 -40.91 85.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.234 -0.916 . . . . 0.0 110.408 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 63.5 t80 -49.63 -38.48 32.3 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.172 -0.955 . . . . 0.0 110.28 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -63.79 -34.07 77.08 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.265 -0.897 . . . . 0.0 110.358 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.49 ' OG1' ' CD1' ' A' ' 50' ' ' TYR . 7.1 p -69.67 -47.04 64.7 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.195 -0.941 . . . . 0.0 110.014 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.49 ' CD1' ' OG1' ' A' ' 49' ' ' THR . 71.8 m-85 -76.39 -20.8 56.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.221 -0.924 . . . . 0.0 109.923 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.67 -12.86 62.53 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.31 0 O-C-N 119.937 -1.919 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.782 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.634 ' CE2' ' NE2' ' A' ' 40' ' ' HIS . 1.1 t80 -125.39 81.94 63.41 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.294 -0.879 . . . . 0.0 110.29 . . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.502 ' HD2' ' ND1' ' A' ' 40' ' ' HIS . 46.9 Cg_endo -71.55 -4.16 14.48 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.049 1.552 . . . . 0.0 109.62 179.227 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.473 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 65.1 mtt180 57.47 36.18 26.72 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.382 -0.824 . . . . 0.0 110.011 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.576 HD13 ' N ' ' A' ' 39' ' ' LEU . 1.9 pp -123.75 174.07 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.524 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.65 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 56.9 p-90 -56.51 -47.7 78.75 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.331 -0.855 . . . . 0.0 111.947 -178.338 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.65 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -51.53 -37.29 48.7 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 120.622 -1.299 . . . . 0.0 110.31 -179.741 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.634 ' NE2' ' CE2' ' A' ' 34' ' ' PHE . 77.1 t60 -51.61 -37.41 49.9 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.943 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.1 m-80 -78.64 -23.07 46.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.18 -0.95 . . . . 0.0 109.71 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 30.2 tp -62.17 -30.9 71.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.443 -0.786 . . . . 0.0 109.964 179.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -60.42 -30.52 71.67 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -59.04 -34.45 71.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.289 -1.124 . . . . 0.0 110.083 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -59.85 -40.54 88.93 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -0.909 . . . . 0.0 110.302 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 84.8 mt -58.29 -40.49 78.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.251 -0.905 . . . . 0.0 110.273 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 70.7 t80 -52.75 -46.09 67.34 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.213 -0.929 . . . . 0.0 110.173 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.17 -34.54 78.62 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.238 -0.914 . . . . 0.0 110.292 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 53.3 m -62.41 -38.26 89.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.158 -0.964 . . . . 0.0 110.165 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.21 13.49 28.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 110.175 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 51.4 94.15 0.01 OUTLIER Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.358 0 O-C-N 119.823 -1.987 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.789 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.6 ' O ' ' CD2' ' A' ' 34' ' ' PHE . 18.6 p90 -132.54 76.95 70.85 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.219 -0.926 . . . . 0.0 110.305 . . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.492 ' O ' ' HB2' ' A' ' 36' ' ' ARG . 46.6 Cg_endo -40.65 -29.95 0.47 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.791 1.416 . . . . 0.0 110.08 179.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 15.5 ttt180 171.67 92.36 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.647 -0.658 . . . . 0.0 109.702 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.533 HD12 ' N ' ' A' ' 39' ' ' LEU . 1.1 pp -102.77 -179.04 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.253 -0.904 . . . . 0.0 110.432 -179.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.638 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 62.5 p-90 -63.8 -47.22 81.76 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.319 -0.863 . . . . 0.0 111.768 -178.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.638 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 11.3 tp -61.0 -25.3 66.79 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.6 -1.313 . . . . 0.0 110.326 -179.509 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.423 ' HB2' HG13 ' A' ' 37' ' ' ILE . 80.6 t60 -67.64 -42.72 81.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.091 -1.006 . . . . 0.0 109.729 179.629 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 37' ' ' ILE . 9.8 p30 -100.92 8.99 42.82 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.224 -0.923 . . . . 0.0 109.728 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.493 ' HB2' ' HA ' ' A' ' 39' ' ' LEU . 8.6 tp -61.08 -30.08 70.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.878 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -63.07 -31.74 81.74 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -62.27 -38.31 88.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -1.166 . . . . 0.0 110.098 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 66.7 m170 -53.97 -39.82 66.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.258 -0.901 . . . . 0.0 110.358 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.428 ' HA ' HG22 ' A' ' 49' ' ' THR . 96.8 mt -57.13 -46.21 84.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.228 -0.92 . . . . 0.0 110.186 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 73.3 t80 -50.97 -38.37 50.43 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 0.0 110.402 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 52' ' ' NH2 . 95.9 mt-10 -65.21 -32.08 73.57 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.093 -1.005 . . . . 0.0 110.305 -179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.528 ' OG1' ' CD1' ' A' ' 50' ' ' TYR . 6.8 p -72.22 -50.18 29.47 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.322 -0.861 . . . . 0.0 110.163 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.528 ' CD1' ' OG1' ' A' ' 49' ' ' THR . 77.6 m-85 -74.02 -24.03 59.5 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.265 -0.897 . . . . 0.0 110.133 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -97.5 -57.99 1.03 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . 0.438 ' N ' ' O ' ' A' ' 48' ' ' GLU . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.921 -1.929 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.213 -0.822 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.632 ' CE1' ' NE2' ' A' ' 40' ' ' HIS . 0.2 OUTLIER -126.82 77.87 74.04 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.252 -0.905 . . . . 0.0 110.409 . . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.472 ' O ' ' HB2' ' A' ' 36' ' ' ARG . 46.2 Cg_endo -68.98 -6.3 17.86 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 124.034 1.544 . . . . 0.0 109.5 179.022 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.472 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 79.9 mtt-85 57.87 38.33 27.1 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.39 -0.819 . . . . 0.0 110.164 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.556 HD13 ' CB ' ' A' ' 39' ' ' LEU . 1.3 pp -115.9 174.53 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.443 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.645 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 60.8 p-90 -59.28 -46.72 87.77 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.22 -0.925 . . . . 0.0 111.725 -178.54 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.645 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 3.5 tt -54.8 -40.94 69.99 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.81 -1.181 . . . . 0.0 110.261 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.632 ' NE2' ' CE1' ' A' ' 34' ' ' PHE . 72.3 t60 -49.17 -40.44 33.09 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.066 -1.021 . . . . 0.0 109.663 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' A' ' 37' ' ' ILE . 5.1 m-80 -78.07 -24.43 47.67 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.364 -0.835 . . . . 0.0 109.476 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 28.9 tp -69.52 -30.38 68.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.478 -0.764 . . . . 0.0 109.699 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -65.91 -27.83 73.13 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -60.17 -33.37 72.11 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.322 -1.105 . . . . 0.0 109.831 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -53.47 -48.74 68.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.322 -0.861 . . . . 0.0 110.042 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 89.9 mt -50.68 -46.01 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.345 -0.847 . . . . 0.0 110.191 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 70.5 t80 -48.44 -40.83 27.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.208 -0.932 . . . . 0.0 110.146 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.51 -40.65 93.24 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.273 -0.892 . . . . 0.0 110.031 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 94.4 m -60.91 -48.88 79.8 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.287 -0.883 . . . . 0.0 110.22 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -72.75 -24.24 60.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.331 -0.856 . . . . 0.0 110.143 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 50.79 -104.36 0.13 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.364 0 O-C-N 119.866 -1.961 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.746 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.502 ' O ' ' CG1' ' A' ' 37' ' ' ILE . 21.5 m-85 -119.93 87.12 37.79 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.208 -0.933 . . . . 0.0 110.122 . . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.451 ' HA ' ' CB ' ' A' ' 39' ' ' LEU . 45.4 Cg_endo -61.91 -10.46 17.54 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.978 1.515 . . . . 0.0 110.539 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 13.4 ttm180 -71.18 -20.69 62.25 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.281 -0.887 . . . . 0.0 111.036 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.66 ' CD1' ' CD1' ' A' ' 38' ' ' TRP . 1.1 pp -73.47 -131.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 120.834 -1.167 . . . . 0.0 110.053 -179.794 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.66 ' CD1' ' CD1' ' A' ' 37' ' ' ILE . 12.3 p-90 -69.54 -16.83 63.51 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.574 -1.329 . . . . 0.0 110.661 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.597 HD11 ' CE2' ' A' ' 38' ' ' TRP . 1.0 OUTLIER -61.18 -30.47 70.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.991 -1.068 . . . . 0.0 109.353 178.923 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -62.53 -38.76 91.21 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.475 -0.766 . . . . 0.0 110.13 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.526 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 24.8 p30 -85.43 -17.95 35.08 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.229 -0.92 . . . . 0.0 110.19 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.492 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 29.4 tp -43.95 -46.08 8.03 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.222 -0.923 . . . . 0.0 109.973 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.446 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -49.41 -34.16 18.41 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.464 ' HB2' ' O ' ' A' ' 41' ' ' ASN . 95.3 mt-30 -59.27 -32.52 70.09 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.125 -1.22 . . . . 0.0 110.145 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -53.58 -44.43 69.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.346 -0.846 . . . . 0.0 109.999 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.564 HG12 ' CE1' ' A' ' 50' ' ' TYR . 7.7 tt -63.63 -33.42 61.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -0.883 . . . . 0.0 110.03 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.478 ' N ' HG23 ' A' ' 46' ' ' ILE . 60.7 t80 -45.08 -51.6 10.0 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.966 . . . . 0.0 109.332 179.569 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -50.13 -44.75 52.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.415 -0.803 . . . . 0.0 109.759 179.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 89.5 m -67.35 -33.81 76.02 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.351 -0.843 . . . . 0.0 110.196 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.564 ' CE1' HG12 ' A' ' 46' ' ' ILE . 13.9 m-30 -71.75 -24.8 61.83 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.279 -0.888 . . . . 0.0 109.801 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.62 7.84 86.89 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.367 0 O-C-N 119.905 -1.938 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.7 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.647 ' CG ' ' O ' ' A' ' 34' ' ' PHE . 20.0 p90 -122.1 105.81 36.82 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.156 -0.965 . . . . 0.0 110.299 . . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.575 ' O ' ' CG ' ' A' ' 36' ' ' ARG . 44.1 Cg_endo -67.49 -40.03 11.3 Favored 'Trans proline' 0 C--N 1.3 -1.986 0 O-C-N 123.775 1.408 . . . . 0.0 109.284 179.448 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.575 ' CG ' ' O ' ' A' ' 35' ' ' PRO . 43.2 mtt180 -162.67 85.22 0.55 Allowed 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.669 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.54 ' CG2' ' HB2' ' A' ' 34' ' ' PHE . 1.3 pt -114.37 163.68 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.842 -1.161 . . . . 0.0 110.417 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.531 ' O ' ' N ' ' A' ' 42' ' ' LEU . 57.6 p-90 -39.83 -45.34 1.77 Allowed 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.234 -0.916 . . . . 0.0 110.869 -179.27 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.5 ' N ' ' CG ' ' A' ' 38' ' ' TRP . 7.6 tt -54.12 -42.82 69.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.939 -1.101 . . . . 0.0 110.03 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 69.2 t60 -59.89 -41.14 90.94 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.344 -0.847 . . . . 0.0 110.037 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.454 ' ND2' ' O ' ' A' ' 37' ' ' ILE . 3.1 p30 -99.39 5.59 46.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.352 -0.842 . . . . 0.0 110.121 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.531 ' N ' ' O ' ' A' ' 38' ' ' TRP . 23.7 tp -58.92 -37.19 76.1 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.425 -0.797 . . . . 0.0 110.187 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.474 ' HA2' HD13 ' A' ' 46' ' ' ILE . . . -56.87 -37.44 78.13 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -56.02 -41.73 75.37 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.198 -1.178 . . . . 0.0 110.177 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.429 ' CD2' ' HA ' ' A' ' 42' ' ' LEU . 74.2 m-70 -52.64 -37.18 58.03 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.233 -0.917 . . . . 0.0 109.955 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.474 HD13 ' HA2' ' A' ' 43' ' ' GLY . 71.0 mt -59.12 -38.65 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.195 -0.941 . . . . 0.0 109.945 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 70.3 t80 -58.45 -34.99 71.46 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.353 -0.842 . . . . 0.0 110.032 179.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.523 ' O ' ' CB ' ' A' ' 49' ' ' THR . 61.2 mm-40 -62.11 147.7 46.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 110.317 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.523 ' CB ' ' O ' ' A' ' 48' ' ' GLU . 2.5 m 71.82 -54.12 0.68 Allowed 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.377 -0.827 . . . . 0.0 110.265 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 18.8 m-30 -72.69 -26.19 61.52 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.285 -0.884 . . . . 0.0 110.556 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.55 99.17 2.5 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.364 0 O-C-N 119.832 -1.981 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . 0.468 ' O ' ' CB ' ' A' ' 36' ' ' ARG . . . . . . . . 0 C--O 1.215 -0.734 . . . . . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.634 ' CG ' ' NE2' ' A' ' 40' ' ' HIS . 4.9 m-30 -52.91 -42.23 89.07 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 110.255 . . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.53 ' HD2' ' N ' ' A' ' 34' ' ' PHE . 45.7 Cg_endo -78.17 9.74 2.96 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 123.652 1.343 . . . . 0.0 110.407 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.468 ' CB ' ' O ' ' A' ' 33' ' ' ACE . 45.7 ttp180 -66.9 -40.38 87.71 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.078 -1.014 . . . . 0.0 109.973 179.577 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.573 ' CG2' ' HB2' ' A' ' 40' ' ' HIS . 0.0 OUTLIER -123.08 129.59 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.193 -0.942 . . . . 0.0 110.418 179.621 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.643 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 58.5 p-90 -52.15 -48.71 64.76 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.451 -0.78 . . . . 0.0 111.802 -178.567 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.643 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 5.8 tt -48.34 -29.2 3.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.694 -1.254 . . . . 0.0 109.476 -179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.634 ' NE2' ' CG ' ' A' ' 34' ' ' PHE . 85.2 t60 -62.24 -27.11 68.77 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.328 -0.857 . . . . 0.0 109.898 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.529 ' ND2' ' N ' ' A' ' 41' ' ' ASN . 1.2 m120 -68.43 -29.86 68.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.378 -0.826 . . . . 0.0 109.461 179.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.428 HD12 ' HA ' ' A' ' 39' ' ' LEU . 7.0 mp -70.58 -30.88 67.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.508 -0.745 . . . . 0.0 109.972 179.704 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -56.45 -37.02 72.58 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 91.2 mt-30 -50.73 -38.4 47.23 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.29 -1.124 . . . . 0.0 110.163 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -59.42 -36.54 76.07 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.255 -0.903 . . . . 0.0 110.053 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.474 HG22 ' CE2' ' A' ' 50' ' ' TYR . 22.0 mm -65.21 -38.35 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.232 -0.918 . . . . 0.0 109.983 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.516 ' O ' ' N ' ' A' ' 51' ' ' GLY . 74.8 t80 -46.41 -49.46 17.99 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.302 -0.874 . . . . 0.0 109.716 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -59.93 -37.02 78.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.394 -0.816 . . . . 0.0 109.957 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 82.5 m -66.72 -38.24 86.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.266 -0.896 . . . . 0.0 110.034 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.474 ' CE2' HG22 ' A' ' 46' ' ' ILE . 97.5 m-85 -107.19 13.62 27.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.254 -0.904 . . . . 0.0 110.206 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 72.86 -94.2 0.68 Allowed Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.32 0 O-C-N 119.823 -1.986 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.775 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.498 ' O ' ' CG1' ' A' ' 37' ' ' ILE . 7.7 m-85 -62.8 126.64 89.08 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.225 -0.922 . . . . 0.0 110.109 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.477 ' HA ' ' CD1' ' A' ' 39' ' ' LEU . 47.1 Cg_endo -62.85 -9.23 15.76 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 123.945 1.497 . . . . 0.0 110.429 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 37.4 ttp85 -72.81 -24.85 60.96 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.215 -0.928 . . . . 0.0 110.784 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.681 ' CD1' ' CD1' ' A' ' 38' ' ' TRP . 1.3 pp -68.66 -139.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.038 -1.039 . . . . 0.0 110.218 -179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.681 ' CD1' ' CD1' ' A' ' 37' ' ' ILE . 46.2 p-90 -66.04 -10.0 35.88 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.661 -1.275 . . . . 0.0 110.4 -179.134 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.593 HD23 ' CZ3' ' A' ' 38' ' ' TRP . 37.5 mt -63.53 -24.75 67.94 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.916 -1.115 . . . . 0.0 108.03 177.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 54.7 t-80 -64.37 -28.98 70.06 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.721 -0.612 . . . . 0.0 109.757 179.632 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 18.3 m-20 -60.51 -35.12 75.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.308 -0.87 . . . . 0.0 109.763 179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.468 ' CD1' ' N ' ' A' ' 42' ' ' LEU . 7.7 mp -69.47 -38.38 77.7 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.39 -0.819 . . . . 0.0 109.898 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -55.72 -34.63 61.04 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -59.38 -36.52 75.94 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.172 -1.193 . . . . 0.0 110.552 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -53.96 -40.47 66.87 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.171 -0.956 . . . . 0.0 110.237 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.456 HD11 HG23 ' A' ' 46' ' ' ILE . 95.2 mt -61.2 -37.61 77.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.205 -0.935 . . . . 0.0 110.367 -179.801 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.475 ' O ' ' N ' ' A' ' 51' ' ' GLY . 71.6 t80 -53.72 -46.76 70.92 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.144 -0.972 . . . . 0.0 110.065 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -56.61 -40.69 75.75 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.287 -0.883 . . . . 0.0 110.179 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 89.0 m -62.78 -33.96 76.25 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.11 -0.994 . . . . 0.0 110.2 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -109.05 10.41 26.13 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.295 -0.878 . . . . 0.0 110.252 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -122.61 -75.59 0.34 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.351 0 O-C-N 119.874 -1.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.701 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.543 ' HB2' ' CE1' ' A' ' 40' ' ' HIS . 63.0 m-85 -125.75 78.31 69.29 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.289 -0.882 . . . . 0.0 110.318 . . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -77.04 0.92 9.22 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.89 1.469 . . . . 0.0 110.012 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.5 mtm105 -68.94 -23.01 64.1 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.309 -0.869 . . . . 0.0 110.657 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.577 HD11 ' N ' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -125.31 122.37 62.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.12 -0.987 . . . . 0.0 111.449 -179.044 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.613 ' CE2' ' HG ' ' A' ' 39' ' ' LEU . 59.1 p-90 -52.31 -41.92 63.36 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.579 -0.701 . . . . 0.0 110.285 179.24 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.613 ' HG ' ' CE2' ' A' ' 38' ' ' TRP . 34.3 mt -48.63 -33.22 9.49 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.88 -1.137 . . . . 0.0 108.595 178.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.543 ' CE1' ' HB2' ' A' ' 34' ' ' PHE . 78.4 t60 -70.02 -34.99 73.99 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.406 0.622 . . . . 0.0 109.674 179.559 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.588 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 0.8 OUTLIER -77.88 -14.47 59.54 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.39 -0.819 . . . . 0.0 109.414 179.818 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.592 HD13 ' CZ3' ' A' ' 38' ' ' TRP . 20.3 mt -69.72 -34.41 73.84 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.382 -0.824 . . . . 0.0 109.762 179.408 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -62.96 -34.11 89.03 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -57.37 -34.75 69.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.19 -1.182 . . . . 0.0 109.667 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -62.83 -42.02 99.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.379 -0.826 . . . . 0.0 109.979 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.404 HG21 ' CD1' ' A' ' 50' ' ' TYR . 94.6 mt -61.29 -43.24 96.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.264 -0.897 . . . . 0.0 110.325 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -47.81 -42.92 27.26 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.284 -0.885 . . . . 0.0 110.52 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -68.72 -36.46 78.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.229 -0.919 . . . . 0.0 110.413 -179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 99.9 m -60.48 -50.22 74.45 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.239 -0.913 . . . . 0.0 110.489 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . 0.404 ' CD1' HG21 ' A' ' 46' ' ' ILE . 70.6 m-85 -72.22 -23.69 61.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.174 -0.954 . . . . 0.0 110.03 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.9 111.59 3.75 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.341 0 O-C-N 119.876 -1.955 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.713 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.58 ' CD1' ' O ' ' A' ' 34' ' ' PHE . 1.3 t80 -59.74 -37.73 53.21 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.166 -0.959 . . . . 0.0 110.371 . . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.555 ' CD ' ' N ' ' A' ' 34' ' ' PHE . 48.8 Cg_endo -81.46 13.68 2.36 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.698 1.368 . . . . 0.0 110.224 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.8 ttp180 -72.41 -37.63 68.62 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.349 -0.844 . . . . 0.0 110.288 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.535 HD11 ' N ' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -125.2 114.82 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.278 -0.889 . . . . 0.0 110.44 -179.831 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.632 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 61.8 p-90 -59.14 -42.08 89.83 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.393 -0.817 . . . . 0.0 110.257 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.632 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 8.2 tt -54.02 -18.36 3.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.053 -1.029 . . . . 0.0 109.664 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' HIS . . . . . 0.528 ' HB2' ' CG2' ' A' ' 37' ' ' ILE . 67.8 t60 -82.59 -13.56 56.33 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.341 -0.849 . . . . 0.0 109.425 179.406 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . 0.521 ' OD1' ' HA ' ' A' ' 38' ' ' TRP . 0.7 OUTLIER -83.31 -26.29 30.74 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.976 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.46 HD13 ' HA ' ' A' ' 39' ' ' LEU . 80.2 mt -64.41 -38.16 90.06 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.478 -0.764 . . . . 0.0 109.157 179.39 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -65.18 -34.99 91.12 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -58.75 -33.72 70.59 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.272 -1.134 . . . . 0.0 110.056 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.425 ' ND1' ' O ' ' A' ' 41' ' ' ASN . 78.2 m80 -53.1 -39.34 63.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.318 -0.864 . . . . 0.0 109.822 179.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.6 mm -58.78 -43.6 88.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.348 -0.845 . . . . 0.0 110.023 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.486 ' O ' ' N ' ' A' ' 51' ' ' GLY . 73.2 t80 -48.87 -46.63 42.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.302 -0.874 . . . . 0.0 110.04 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -64.61 -38.45 91.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 110.107 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 57.2 m -65.27 -36.03 82.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.143 -0.973 . . . . 0.0 110.167 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -110.68 14.96 22.23 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.323 -0.861 . . . . 0.0 110.305 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -110.27 -131.1 5.97 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.343 0 O-C-N 119.874 -1.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.72 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.446 ' O ' HG12 ' A' ' 37' ' ' ILE . 2.6 m-30 -67.03 124.99 90.22 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.269 -0.894 . . . . 0.0 110.367 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.67 ' HA ' HD23 ' A' ' 39' ' ' LEU . 48.5 Cg_endo -53.54 -19.14 13.0 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 124.085 1.571 . . . . 0.0 109.998 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.8 tpt180 -52.09 -31.49 30.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.324 -0.86 . . . . 0.0 110.403 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.553 HD12 ' CG ' ' A' ' 38' ' ' TRP . 1.1 pp -59.73 -156.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.076 -1.015 . . . . 0.0 110.312 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.625 ' HZ3' HD12 ' A' ' 42' ' ' LEU . 19.9 p-90 -55.38 -18.61 7.01 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.133 -0.979 . . . . 0.0 110.554 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.67 HD23 ' HA ' ' A' ' 35' ' ' PRO . 25.3 tp -68.03 -15.23 63.51 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.07 -1.019 . . . . 0.0 109.932 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 86.4 t60 -78.97 -40.07 32.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.268 -0.895 . . . . 0.0 110.044 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.549 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 25.8 p30 -67.74 -22.92 65.21 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.281 -0.887 . . . . 0.0 110.275 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.625 HD12 ' HZ3' ' A' ' 38' ' ' TRP . 15.5 mt -69.52 -32.35 71.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 110.216 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -62.17 -31.73 80.03 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.67 -32.9 72.08 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.278 -1.131 . . . . 0.0 110.198 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -58.23 -43.71 87.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.261 -0.899 . . . . 0.0 110.364 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 78.7 mt -55.01 -43.41 69.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.18 -0.95 . . . . 0.0 110.321 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -51.25 -45.16 61.94 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.24 -0.912 . . . . 0.0 110.118 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.6 -36.99 84.52 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.242 -0.911 . . . . 0.0 110.029 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 70.5 m -62.46 -37.03 84.34 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.18 -0.95 . . . . 0.0 110.026 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -106.6 13.59 28.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.869 . . . . 0.0 110.176 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.14 -126.04 5.76 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.323 0 O-C-N 119.872 -1.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.744 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -130.95 79.75 70.88 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.252 -0.905 . . . . 0.0 110.056 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.15 -8.37 20.02 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.987 1.519 . . . . 0.0 110.489 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -64.53 -25.07 67.82 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.257 -0.902 . . . . 0.0 110.534 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.789 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.6 OUTLIER -121.82 121.26 63.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.185 -0.947 . . . . 0.0 110.314 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.856 ' HZ3' HD22 ' A' ' 42' ' ' LEU . 65.5 p-90 -60.84 -42.4 97.7 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.408 -0.807 . . . . 0.0 110.87 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.599 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 14.8 tp -54.37 -21.95 10.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.931 -1.106 . . . . 0.0 109.73 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.789 ' HB2' HG23 ' A' ' 37' ' ' ILE . 49.1 t-80 -75.63 -39.46 57.75 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.439 -0.788 . . . . 0.0 109.672 179.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -104.71 5.51 33.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.261 -0.899 . . . . 0.0 109.67 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.856 HD22 ' HZ3' ' A' ' 38' ' ' TRP . 19.4 tp -63.11 -38.06 89.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.302 -0.874 . . . . 0.0 110.042 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -55.81 -36.71 66.8 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -63.92 -34.33 77.73 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.383 -1.069 . . . . 0.0 109.971 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -58.34 -46.13 86.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.29 -0.881 . . . . 0.0 110.218 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 17.3 mm -56.49 -43.93 79.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.282 -0.886 . . . . 0.0 110.144 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.495 ' O ' ' N ' ' A' ' 51' ' ' GLY . 66.2 t80 -45.58 -46.49 14.26 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.148 -0.97 . . . . 0.0 109.735 179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -61.46 -37.51 83.85 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.417 -0.802 . . . . 0.0 110.038 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 64.4 m -68.59 -32.08 71.73 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.185 -0.947 . . . . 0.0 110.01 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -111.79 15.72 20.77 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.357 -0.839 . . . . 0.0 110.093 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 49.22 47.55 33.89 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.323 0 O-C-N 119.877 -1.955 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.756 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.447 ' O ' HG12 ' A' ' 37' ' ' ILE . 0.3 OUTLIER -123.96 75.27 57.81 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.17 . . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.624 ' HA ' HD23 ' A' ' 39' ' ' LEU . 49.1 Cg_endo -59.73 -16.68 38.6 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 124.015 1.534 . . . . 0.0 110.346 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -56.63 -30.27 63.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.37 -0.831 . . . . 0.0 110.495 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.591 HD12 ' CG ' ' A' ' 38' ' ' TRP . 1.1 pp -58.68 -162.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.192 -0.943 . . . . 0.0 110.492 -179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.591 ' CG ' HD12 ' A' ' 37' ' ' ILE . 24.0 p-90 -53.85 -16.68 1.9 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.169 -0.957 . . . . 0.0 110.388 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.787 HD12 HD22 ' A' ' 42' ' ' LEU . 16.5 tp -66.99 -26.53 66.84 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.999 -1.063 . . . . 0.0 109.325 179.24 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.465 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 86.4 t60 -60.85 -31.6 71.04 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.409 -0.807 . . . . 0.0 109.691 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.568 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 18.2 p30 -95.64 -12.89 24.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.4 -0.813 . . . . 0.0 109.736 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.787 HD22 HD12 ' A' ' 39' ' ' LEU . 27.9 tp -45.17 -43.21 9.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.394 -0.816 . . . . 0.0 110.148 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -48.21 -31.19 8.4 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.402 ' HB2' ' O ' ' A' ' 41' ' ' ASN . 94.5 mt-30 -59.48 -34.98 73.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.367 -1.078 . . . . 0.0 109.925 179.818 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -51.48 -44.53 62.49 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.879 . . . . 0.0 109.915 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.406 HG23 ' CE2' ' A' ' 50' ' ' TYR . 21.0 mm -55.13 -45.73 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.939 . . . . 0.0 109.999 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.453 ' O ' ' N ' ' A' ' 51' ' ' GLY . 65.6 t80 -50.29 -46.33 55.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.267 -0.896 . . . . 0.0 109.838 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -68.23 -35.7 78.34 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.378 -0.826 . . . . 0.0 109.904 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 51.5 m -66.3 -36.18 82.3 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.256 -0.902 . . . . 0.0 109.964 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 0.406 ' CE2' HG23 ' A' ' 46' ' ' ILE . 90.7 m-85 -111.8 14.23 21.05 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.318 -0.864 . . . . 0.0 110.098 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -71.36 132.26 20.61 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.291 0 O-C-N 119.895 -1.944 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.705 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.668 ' HB2' ' CE1' ' A' ' 40' ' ' HIS . 0.4 OUTLIER -124.31 82.57 57.65 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 110.2 . . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.82 -6.58 18.36 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 124.041 1.548 . . . . 0.0 110.138 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 63.0 mtt180 -61.27 -30.89 70.75 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.292 -0.88 . . . . 0.0 110.476 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.854 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.7 OUTLIER -124.14 125.59 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.055 -1.028 . . . . 0.0 110.846 -179.611 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.752 ' HZ3' HD22 ' A' ' 42' ' ' LEU . 67.8 p-90 -61.13 -45.06 96.2 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.472 -0.767 . . . . 0.0 110.753 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.726 HD23 ' O ' ' A' ' 39' ' ' LEU . 8.5 tt -50.26 -27.22 5.69 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.01 -1.056 . . . . 0.0 109.628 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.854 ' HB2' HG23 ' A' ' 37' ' ' ILE . 42.4 t-80 -70.72 -39.37 73.42 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.451 -0.781 . . . . 0.0 109.557 179.466 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 14.2 p30 -105.17 10.25 33.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.416 -0.802 . . . . 0.0 109.744 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.752 HD22 ' HZ3' ' A' ' 38' ' ' TRP . 24.3 tp -60.78 -35.52 76.65 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.37 -0.831 . . . . 0.0 110.23 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -61.46 -33.76 85.91 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -59.15 -38.41 79.63 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.184 -1.186 . . . . 0.0 110.072 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -56.72 -35.78 68.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.388 -0.82 . . . . 0.0 110.302 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 94.5 mt -61.72 -40.21 86.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.118 -0.989 . . . . 0.0 110.371 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.411 ' O ' ' N ' ' A' ' 51' ' ' GLY . 75.5 t80 -54.27 -46.92 72.79 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.262 -0.899 . . . . 0.0 110.26 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -61.49 -38.06 85.95 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.177 -0.952 . . . . 0.0 110.124 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 54.2 m -61.36 -38.39 86.79 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.321 -0.862 . . . . 0.0 110.141 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -107.61 11.4 28.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.234 -0.916 . . . . 0.0 110.241 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 59.86 -121.22 25.94 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.353 0 O-C-N 119.783 -2.01 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.717 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.598 ' HB2' ' CE1' ' A' ' 40' ' ' HIS . 0.4 OUTLIER -125.12 79.29 65.9 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.237 -0.914 . . . . 0.0 110.219 . . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.03 -6.87 18.19 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.974 1.513 . . . . 0.0 110.224 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.586 ' HD2' ' CE2' ' A' ' 34' ' ' PHE . 95.0 mtt180 -61.14 -32.49 72.2 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.265 -0.897 . . . . 0.0 110.345 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.853 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.5 OUTLIER -122.8 124.32 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.223 -0.923 . . . . 0.0 110.308 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.843 ' HZ3' HD22 ' A' ' 42' ' ' LEU . 63.5 p-90 -60.96 -41.78 97.0 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.364 -0.835 . . . . 0.0 110.989 -179.502 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.625 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 15.6 tp -54.1 -24.19 16.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.946 -1.096 . . . . 0.0 109.493 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.853 ' HB2' HG23 ' A' ' 37' ' ' ILE . 50.4 t-80 -72.27 -47.09 52.77 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.575 -0.703 . . . . 0.0 109.687 179.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -99.83 8.09 44.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.326 -0.859 . . . . 0.0 109.833 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.843 HD22 ' HZ3' ' A' ' 38' ' ' TRP . 31.0 tp -54.36 -40.11 67.8 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.376 -0.827 . . . . 0.0 110.01 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -53.61 -37.58 56.82 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.069 -1.612 . . . . 0.0 109.069 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -61.8 -34.48 75.98 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 0.0 109.974 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -54.5 -43.57 71.95 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.235 -0.916 . . . . 0.0 109.888 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 mm -61.16 -37.96 78.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.9 . . . . 0.0 109.974 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 51' ' ' GLY . 64.4 t80 -46.88 -47.85 21.26 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.153 -0.967 . . . . 0.0 109.761 179.7 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -64.4 -37.8 88.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.361 -0.837 . . . . 0.0 109.978 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 58.9 m -63.76 -35.02 79.2 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.233 -0.917 . . . . 0.0 110.103 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -110.9 14.54 22.08 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.345 -0.847 . . . . 0.0 110.091 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 59.54 -160.59 18.11 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.339 0 O-C-N 119.849 -1.971 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.726 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -122.32 80.55 45.27 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.247 -0.908 . . . . 0.0 110.097 . . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -63.7 -16.67 56.1 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 124.005 1.529 . . . . 0.0 110.354 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 37.1 ttt180 -58.33 -35.16 71.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.357 -0.839 . . . . 0.0 110.294 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 1.5 pp -71.53 -3.01 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.233 -0.917 . . . . 0.0 110.396 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 39' ' ' LEU . 4.0 m95 -104.91 159.44 15.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.238 -0.914 . . . . 0.0 110.173 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.506 ' HB2' ' O ' ' A' ' 38' ' ' TRP . 17.6 mt 69.11 -50.72 0.6 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.459 -0.776 . . . . 0.0 110.999 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -61.7 -45.3 94.55 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.967 -1.083 . . . . 0.0 110.361 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -71.45 -33.25 69.19 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.242 -0.911 . . . . 0.0 110.418 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 56.3 mt -69.67 -25.17 63.77 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.265 -0.897 . . . . 0.0 109.992 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -60.18 -31.6 73.74 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -60.27 -35.26 75.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.233 -1.157 . . . . 0.0 109.993 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -52.94 -39.29 62.76 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.313 -0.867 . . . . 0.0 109.948 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.014 HG23 ' CE1' ' A' ' 50' ' ' TYR . 91.1 mt -59.01 -46.77 91.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.234 -0.916 . . . . 0.0 110.014 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.415 ' C ' ' O ' ' A' ' 46' ' ' ILE . 75.9 t80 -42.53 -52.16 4.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.436 -0.79 . . . . 0.0 109.797 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -59.83 -43.88 94.34 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 48.1 m -61.37 -40.02 92.79 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.359 -0.838 . . . . 0.0 109.601 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 1.014 ' CE1' HG23 ' A' ' 46' ' ' ILE . 29.5 p90 -174.87 98.94 0.08 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.383 -0.823 . . . . 0.0 110.085 179.569 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.5 103.99 2.23 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.352 0 O-C-N 119.874 -1.956 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.731 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.4 ' HB2' ' ND1' ' A' ' 40' ' ' HIS . 22.5 m-85 -127.38 80.02 72.39 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.238 -0.914 . . . . 0.0 110.164 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -66.08 -8.12 19.17 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 O-C-N 123.956 1.503 . . . . 0.0 110.38 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 82.2 mtm180 -66.1 -26.34 67.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.267 -0.896 . . . . 0.0 110.624 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.783 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.3 OUTLIER -123.9 116.76 48.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.052 -1.03 . . . . 0.0 110.699 -179.532 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.725 ' CH2' HD12 ' A' ' 39' ' ' LEU . 55.3 p-90 -56.47 -41.07 75.94 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.432 -0.792 . . . . 0.0 110.733 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.725 HD12 ' CH2' ' A' ' 38' ' ' TRP . 0.7 OUTLIER -61.82 -12.75 18.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.18 -0.95 . . . . 0.0 110.757 -179.246 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.783 ' HB2' HG23 ' A' ' 37' ' ' ILE . 38.6 t-80 -75.66 -24.75 56.39 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.049 -1.032 . . . . 0.0 109.942 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.441 ' OD1' ' HA ' ' A' ' 38' ' ' TRP . 6.9 m120 -78.47 -17.73 55.87 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.296 -0.877 . . . . 0.0 109.08 179.465 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.724 HD13 ' HA ' ' A' ' 39' ' ' LEU . 9.2 mp -72.57 -32.92 66.4 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.244 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.475 ' O ' ' HB ' ' A' ' 46' ' ' ILE . . . -56.3 -42.42 88.72 Favored Glycine 0 N--CA 1.487 2.082 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 179.394 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -49.88 -40.07 41.52 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -1.141 . . . . 0.0 109.552 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 82.9 t60 -53.51 -35.39 60.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.232 -0.918 . . . . 0.0 109.452 179.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.836 HG22 ' CE1' ' A' ' 50' ' ' TYR . 95.6 mt -62.83 -43.45 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.337 -0.852 . . . . 0.0 109.355 179.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.56 ' HA ' ' CE1' ' A' ' 50' ' ' TYR . 71.5 t80 -43.18 -46.89 6.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.37 -0.831 . . . . 0.0 109.558 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -66.21 -30.59 71.08 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.337 -0.852 . . . . 0.0 109.796 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.48 ' HB ' ' O ' ' A' ' 46' ' ' ILE . 88.3 m -63.19 -45.54 91.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.25 -0.906 . . . . 0.0 109.886 179.706 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 0.836 ' CE1' HG22 ' A' ' 46' ' ' ILE . 41.8 p90 -116.99 25.87 10.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.279 -0.888 . . . . 0.0 110.132 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 55.97 -165.18 4.41 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.324 0 O-C-N 119.857 -1.966 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.769 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.565 ' HB2' ' CD2' ' A' ' 40' ' ' HIS . 8.4 m-85 -122.8 84.2 49.55 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.295 -0.878 . . . . 0.0 110.216 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -66.66 -8.39 20.99 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.989 1.521 . . . . 0.0 110.183 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 54.2 mtt85 -58.9 -33.57 70.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.428 -0.795 . . . . 0.0 110.857 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.938 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.2 OUTLIER -127.01 114.12 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.014 -1.054 . . . . 0.0 110.74 -179.45 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.652 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 41.6 p-90 -48.99 -38.71 24.07 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.573 -0.704 . . . . 0.0 110.576 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.652 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 9.2 tt -58.91 -27.9 65.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.257 -0.902 . . . . 0.0 110.08 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.938 ' HB2' HG23 ' A' ' 37' ' ' ILE . 54.7 t-80 -65.19 -35.54 81.38 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.328 -0.858 . . . . 0.0 110.115 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -79.4 -17.11 55.05 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.137 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.409 HD12 ' HA ' ' A' ' 42' ' ' LEU . 18.2 tp -74.39 -24.51 59.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.484 -0.76 . . . . 0.0 109.569 179.214 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -69.32 -29.43 71.87 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.04 -1.624 . . . . 0.0 109.04 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -58.63 -30.52 67.34 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.413 -1.051 . . . . 0.0 109.795 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -60.32 -38.66 84.41 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.407 -0.808 . . . . 0.0 110.373 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 22.9 mm -62.14 -37.2 77.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.123 -0.985 . . . . 0.0 110.306 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.474 ' O ' ' N ' ' A' ' 51' ' ' GLY . 75.0 t80 -54.15 -46.74 72.35 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.188 -0.945 . . . . 0.0 110.171 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -66.45 -38.01 86.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.205 -0.934 . . . . 0.0 110.39 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.9 m -65.21 -38.82 91.64 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.177 -0.952 . . . . 0.0 110.227 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -111.27 17.62 20.06 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.279 -0.888 . . . . 0.0 110.135 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -127.6 -108.54 1.49 Allowed Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.337 0 O-C-N 119.903 -1.939 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.759 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.817 ' O ' HG22 ' A' ' 37' ' ' ILE . 2.4 m-85 -124.7 79.23 63.35 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.26 -0.9 . . . . 0.0 110.156 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -55.71 -21.51 32.39 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.934 1.492 . . . . 0.0 110.468 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.484 ' O ' ' HB3' ' A' ' 40' ' ' HIS . 63.3 mtt180 -56.99 -39.74 75.26 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.207 -0.933 . . . . 0.0 110.484 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.998 HD13 ' O ' ' A' ' 37' ' ' ILE . 0.0 OUTLIER -57.28 -28.55 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.22 -0.925 . . . . 0.0 110.218 -179.753 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.608 ' HZ3' HD13 ' A' ' 42' ' ' LEU . 17.3 m95 -98.29 146.24 25.86 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.172 -0.955 . . . . 0.0 110.838 -179.559 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.539 ' HB2' ' O ' ' A' ' 38' ' ' TRP . 28.6 mt 72.49 -44.72 0.6 Allowed 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.85 -0.531 . . . . 0.0 111.171 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.484 ' HB3' ' O ' ' A' ' 36' ' ' ARG . 58.1 t-80 -58.96 -40.44 84.73 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.677 -1.264 . . . . 0.0 110.207 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.474 ' HB2' ' OE1' ' A' ' 44' ' ' GLN . 47.9 p-10 -123.49 14.35 9.53 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.179 -0.951 . . . . 0.0 110.189 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.608 HD13 ' HZ3' ' A' ' 38' ' ' TRP . 13.6 tp -59.83 -29.66 68.41 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.25 -0.906 . . . . 0.0 110.337 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -60.55 -26.74 64.97 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.474 ' OE1' ' HB2' ' A' ' 41' ' ' ASN . 94.2 mt-30 -71.25 -22.95 61.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.314 -1.11 . . . . 0.0 110.231 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -66.26 -46.09 78.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.324 -0.86 . . . . 0.0 110.563 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.45 ' O ' ' N ' ' A' ' 50' ' ' TYR . 17.8 pt -76.97 -10.61 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.21 -0.932 . . . . 0.0 110.539 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.505 ' C ' ' CD1' ' A' ' 47' ' ' TYR . 6.8 t80 -62.45 -49.24 76.24 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.14 -0.975 . . . . 0.0 110.22 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -56.82 -33.9 67.19 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.149 -0.969 . . . . 0.0 110.359 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 69.9 m -101.72 -73.52 0.65 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.328 -0.858 . . . . 0.0 110.707 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 0.45 ' N ' ' O ' ' A' ' 46' ' ' ILE . 93.1 m-85 -65.22 -33.66 76.53 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.271 -0.893 . . . . 0.0 110.454 -179.724 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 47' ' ' TYR . . . 77.95 41.13 19.26 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.317 0 O-C-N 119.858 -1.966 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.723 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.482 ' HB2' ' CE1' ' A' ' 40' ' ' HIS . 1.6 m-85 -122.77 83.2 49.13 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.314 -0.866 . . . . 0.0 110.201 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -71.19 -4.46 14.96 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.021 1.537 . . . . 0.0 110.128 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.448 ' CZ ' ' CE2' ' A' ' 34' ' ' PHE . 57.0 mtm180 -66.7 -26.95 67.27 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.304 -0.872 . . . . 0.0 110.582 -179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.789 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.5 OUTLIER -122.97 119.39 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.035 -1.041 . . . . 0.0 110.757 -179.697 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.643 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 54.0 p-90 -56.99 -42.43 80.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.437 -0.79 . . . . 0.0 110.561 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.643 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 16.8 tp -51.62 -29.5 17.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.072 -1.017 . . . . 0.0 109.367 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.789 ' HB2' HG23 ' A' ' 37' ' ' ILE . 39.4 t-80 -75.18 -44.22 47.82 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.519 -0.738 . . . . 0.0 109.186 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -79.82 -11.32 59.83 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.345 -0.847 . . . . 0.0 109.316 179.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.515 HD23 ' HZ3' ' A' ' 38' ' ' TRP . 18.9 tp -75.01 -28.11 60.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.419 -0.801 . . . . 0.0 109.801 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -65.14 -31.7 81.58 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -60.72 -35.59 76.73 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.471 -1.017 . . . . 0.0 109.408 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -59.26 -43.19 92.5 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.393 -0.817 . . . . 0.0 109.742 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 87.2 mt -54.74 -47.3 74.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.316 -0.865 . . . . 0.0 110.079 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 71.0 t80 -46.37 -43.88 16.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.237 -0.914 . . . . 0.0 110.077 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 74.7 mm-40 -64.13 -38.16 90.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.332 -0.855 . . . . 0.0 110.073 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 84.8 m -61.02 -49.09 78.8 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.254 -0.904 . . . . 0.0 110.245 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 0.485 ' O ' ' N ' ' A' ' 52' ' ' NH2 . 68.4 m-85 -74.54 -22.81 58.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 110.106 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 62.8 -75.59 0.03 OUTLIER Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . 0.485 ' N ' ' O ' ' A' ' 50' ' ' TYR . . . . . . . . 0 C--N 1.306 -1.32 0 O-C-N 119.919 -1.93 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.74 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.51 ' O ' ' CG1' ' A' ' 37' ' ' ILE . 20.2 m-85 -126.12 72.14 70.59 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.199 -0.938 . . . . 0.0 110.312 . . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.572 ' CB ' HD23 ' A' ' 39' ' ' LEU . 46.2 Cg_endo -51.21 -19.85 6.93 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 O-C-N 124.01 1.531 . . . . 0.0 110.436 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.405 ' O ' ' O ' ' A' ' 37' ' ' ILE . 81.7 mtt-85 -61.91 -26.83 68.4 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.207 -0.933 . . . . 0.0 110.464 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.566 HD12 ' CG ' ' A' ' 38' ' ' TRP . 1.4 pp -60.61 -151.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.139 -0.976 . . . . 0.0 110.538 -179.405 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.566 ' CG ' HD12 ' A' ' 37' ' ' ILE . 12.7 p-90 -57.29 -22.99 45.54 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.917 -1.114 . . . . 0.0 110.932 -178.794 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.572 HD23 ' CB ' ' A' ' 35' ' ' PRO . 18.8 tp -54.91 -28.87 54.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.804 -1.185 . . . . 0.0 108.632 179.081 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -62.85 -27.52 69.4 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 178.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.45 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 2.6 m120 -58.26 -45.72 87.32 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.386 -0.821 . . . . 0.0 109.271 179.207 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.447 HD11 ' HZ3' ' A' ' 38' ' ' TRP . 46.5 mt -56.37 -40.33 74.38 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.424 -0.798 . . . . 0.0 109.541 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -52.29 -27.97 25.84 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.45 ' HB2' ' O ' ' A' ' 41' ' ' ASN . 95.3 mt-30 -59.1 -36.2 74.73 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.256 -1.143 . . . . 0.0 110.112 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -55.08 -43.41 73.91 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.275 -0.891 . . . . 0.0 110.448 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 93.8 mt -60.51 -40.91 85.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.234 -0.916 . . . . 0.0 110.408 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 63.5 t80 -49.63 -38.48 32.3 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.172 -0.955 . . . . 0.0 110.28 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -63.79 -34.07 77.08 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.265 -0.897 . . . . 0.0 110.358 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.49 ' OG1' ' CD1' ' A' ' 50' ' ' TYR . 7.1 p -69.67 -47.04 64.7 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.195 -0.941 . . . . 0.0 110.014 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 0.49 ' CD1' ' OG1' ' A' ' 49' ' ' THR . 71.8 m-85 -76.39 -20.8 56.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.221 -0.924 . . . . 0.0 109.923 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.67 -12.86 62.53 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.31 0 O-C-N 119.937 -1.919 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.782 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.634 ' CE2' ' NE2' ' A' ' 40' ' ' HIS . 1.1 t80 -125.39 81.94 63.41 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.294 -0.879 . . . . 0.0 110.29 . . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.645 ' O ' HG23 ' A' ' 37' ' ' ILE . 46.9 Cg_endo -71.55 -4.16 14.48 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.049 1.552 . . . . 0.0 109.62 179.227 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.465 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 65.1 mtt180 57.47 36.18 26.72 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.382 -0.824 . . . . 0.0 110.011 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.89 HD11 ' HB3' ' A' ' 39' ' ' LEU . 1.9 pp -123.75 174.07 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.524 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 1.109 ' CH2' HD12 ' A' ' 39' ' ' LEU . 56.9 p-90 -56.51 -47.7 78.75 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.331 -0.855 . . . . 0.0 111.947 -178.338 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.109 HD12 ' CH2' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -51.53 -37.29 48.7 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 120.622 -1.299 . . . . 0.0 110.31 -179.741 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.634 ' NE2' ' CE2' ' A' ' 34' ' ' PHE . 77.1 t60 -51.61 -37.41 49.9 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.943 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -78.64 -23.07 46.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.18 -0.95 . . . . 0.0 109.71 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.402 ' HB3' ' O ' ' A' ' 39' ' ' LEU . 30.2 tp -62.17 -30.9 71.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.443 -0.786 . . . . 0.0 109.964 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -60.42 -30.52 71.67 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -59.04 -34.45 71.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.289 -1.124 . . . . 0.0 110.083 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -59.85 -40.54 88.93 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -0.909 . . . . 0.0 110.302 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 84.8 mt -58.29 -40.49 78.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.251 -0.905 . . . . 0.0 110.273 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 70.7 t80 -52.75 -46.09 67.34 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.213 -0.929 . . . . 0.0 110.173 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.17 -34.54 78.62 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.238 -0.914 . . . . 0.0 110.292 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 53.3 m -62.41 -38.26 89.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.158 -0.964 . . . . 0.0 110.165 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.21 13.49 28.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 110.175 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 51.4 94.15 0.01 OUTLIER Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.358 0 O-C-N 119.823 -1.987 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.789 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.6 ' CD2' ' O ' ' A' ' 34' ' ' PHE . 18.6 p90 -132.54 76.95 70.85 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.219 -0.926 . . . . 0.0 110.305 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.507 ' O ' ' HB2' ' A' ' 36' ' ' ARG . 46.6 Cg_endo -40.65 -29.95 0.47 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.791 1.416 . . . . 0.0 110.08 179.702 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.507 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 15.5 ttt180 171.67 92.36 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.647 -0.658 . . . . 0.0 109.702 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.689 HD12 ' H ' ' A' ' 39' ' ' LEU . 1.1 pp -102.77 -179.04 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.253 -0.904 . . . . 0.0 110.432 -179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.704 ' CH2' HD13 ' A' ' 39' ' ' LEU . 62.5 p-90 -63.8 -47.22 81.76 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.319 -0.863 . . . . 0.0 111.768 -178.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.704 HD13 ' CH2' ' A' ' 38' ' ' TRP . 11.3 tp -61.0 -25.3 66.79 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.6 -1.313 . . . . 0.0 110.326 -179.509 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.463 ' HB2' HG13 ' A' ' 37' ' ' ILE . 80.6 t60 -67.64 -42.72 81.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.091 -1.006 . . . . 0.0 109.729 179.629 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 37' ' ' ILE . 9.8 p30 -100.92 8.99 42.82 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.224 -0.923 . . . . 0.0 109.728 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.685 HD22 HD12 ' A' ' 39' ' ' LEU . 8.6 tp -61.08 -30.08 70.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.878 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -63.07 -31.74 81.74 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -62.27 -38.31 88.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -1.166 . . . . 0.0 110.098 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 66.7 m170 -53.97 -39.82 66.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.258 -0.901 . . . . 0.0 110.358 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 96.8 mt -57.13 -46.21 84.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.228 -0.92 . . . . 0.0 110.186 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 73.3 t80 -50.97 -38.37 50.43 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 0.0 110.402 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 52' ' ' NH2 . 95.9 mt-10 -65.21 -32.08 73.57 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.093 -1.005 . . . . 0.0 110.305 -179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.528 ' OG1' ' CD1' ' A' ' 50' ' ' TYR . 6.8 p -72.22 -50.18 29.47 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.322 -0.861 . . . . 0.0 110.163 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 0.528 ' CD1' ' OG1' ' A' ' 49' ' ' THR . 77.6 m-85 -74.02 -24.03 59.5 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.265 -0.897 . . . . 0.0 110.133 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -97.5 -57.99 1.03 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . 0.441 ' N ' ' O ' ' A' ' 48' ' ' GLU . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.921 -1.929 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.213 -0.822 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.632 ' CE1' ' NE2' ' A' ' 40' ' ' HIS . 0.2 OUTLIER -126.82 77.87 74.04 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.252 -0.905 . . . . 0.0 110.409 . . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.482 ' O ' HG23 ' A' ' 37' ' ' ILE . 46.2 Cg_endo -68.98 -6.3 17.86 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 124.034 1.544 . . . . 0.0 109.5 179.022 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.465 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 79.9 mtt-85 57.87 38.33 27.1 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.39 -0.819 . . . . 0.0 110.164 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.746 HD11 ' HB3' ' A' ' 39' ' ' LEU . 1.3 pp -115.9 174.53 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.443 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.645 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 60.8 p-90 -59.28 -46.72 87.77 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.22 -0.925 . . . . 0.0 111.725 -178.54 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.746 ' HB3' HD11 ' A' ' 37' ' ' ILE . 3.5 tt -54.8 -40.94 69.99 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.81 -1.181 . . . . 0.0 110.261 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.632 ' NE2' ' CE1' ' A' ' 34' ' ' PHE . 72.3 t60 -49.17 -40.44 33.09 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.066 -1.021 . . . . 0.0 109.663 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -78.07 -24.43 47.67 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.364 -0.835 . . . . 0.0 109.476 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.616 HD22 ' HZ3' ' A' ' 38' ' ' TRP . 28.9 tp -69.52 -30.38 68.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.478 -0.764 . . . . 0.0 109.699 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -65.91 -27.83 73.13 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -60.17 -33.37 72.11 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.322 -1.105 . . . . 0.0 109.831 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -53.47 -48.74 68.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.322 -0.861 . . . . 0.0 110.042 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 89.9 mt -50.68 -46.01 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.345 -0.847 . . . . 0.0 110.191 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 70.5 t80 -48.44 -40.83 27.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.208 -0.932 . . . . 0.0 110.146 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.51 -40.65 93.24 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.273 -0.892 . . . . 0.0 110.031 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 94.4 m -60.91 -48.88 79.8 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.287 -0.883 . . . . 0.0 110.22 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -72.75 -24.24 60.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.331 -0.856 . . . . 0.0 110.143 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 50.79 -104.36 0.13 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.364 0 O-C-N 119.866 -1.961 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.746 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.524 ' O ' HG12 ' A' ' 37' ' ' ILE . 21.5 m-85 -119.93 87.12 37.79 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.208 -0.933 . . . . 0.0 110.122 . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.525 ' HA ' ' HB2' ' A' ' 39' ' ' LEU . 45.4 Cg_endo -61.91 -10.46 17.54 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.978 1.515 . . . . 0.0 110.539 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 13.4 ttm180 -71.18 -20.69 62.25 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.281 -0.887 . . . . 0.0 111.036 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.882 HD11 ' CD1' ' A' ' 39' ' ' LEU . 1.1 pp -73.47 -131.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 120.834 -1.167 . . . . 0.0 110.053 -179.794 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.778 ' CD1' HD12 ' A' ' 37' ' ' ILE . 12.3 p-90 -69.54 -16.83 63.51 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.574 -1.329 . . . . 0.0 110.661 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.882 ' CD1' HD11 ' A' ' 37' ' ' ILE . 1.0 OUTLIER -61.18 -30.47 70.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.991 -1.068 . . . . 0.0 109.353 178.923 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -62.53 -38.76 91.21 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.475 -0.766 . . . . 0.0 110.13 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.561 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 24.8 p30 -85.43 -17.95 35.08 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.229 -0.92 . . . . 0.0 110.19 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.492 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 29.4 tp -43.95 -46.08 8.03 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.222 -0.923 . . . . 0.0 109.973 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.703 ' O ' HG22 ' A' ' 46' ' ' ILE . . . -49.41 -34.16 18.41 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.45 ' HB2' ' O ' ' A' ' 41' ' ' ASN . 95.3 mt-30 -59.27 -32.52 70.09 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.125 -1.22 . . . . 0.0 110.145 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -53.58 -44.43 69.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.346 -0.846 . . . . 0.0 109.999 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.703 HG22 ' O ' ' A' ' 43' ' ' GLY . 7.7 tt -63.63 -33.42 61.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -0.883 . . . . 0.0 110.03 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 60.7 t80 -45.08 -51.6 10.0 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.966 . . . . 0.0 109.332 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -50.13 -44.75 52.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.415 -0.803 . . . . 0.0 109.759 179.433 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 89.5 m -67.35 -33.81 76.02 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.351 -0.843 . . . . 0.0 110.196 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 0.574 ' CE1' HG12 ' A' ' 46' ' ' ILE . 13.9 m-30 -71.75 -24.8 61.83 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.279 -0.888 . . . . 0.0 109.801 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.62 7.84 86.89 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.367 0 O-C-N 119.905 -1.938 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.7 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.647 ' CG ' ' O ' ' A' ' 34' ' ' PHE . 20.0 p90 -122.1 105.81 36.82 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.156 -0.965 . . . . 0.0 110.299 . . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.575 ' O ' ' CG ' ' A' ' 36' ' ' ARG . 44.1 Cg_endo -67.49 -40.03 11.3 Favored 'Trans proline' 0 C--N 1.3 -1.986 0 O-C-N 123.775 1.408 . . . . 0.0 109.284 179.448 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.575 ' CG ' ' O ' ' A' ' 35' ' ' PRO . 43.2 mtt180 -162.67 85.22 0.55 Allowed 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.669 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.628 HD11 ' HB3' ' A' ' 39' ' ' LEU . 1.3 pt -114.37 163.68 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.842 -1.161 . . . . 0.0 110.417 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.851 ' HA ' HD22 ' A' ' 41' ' ' ASN . 57.6 p-90 -39.83 -45.34 1.77 Allowed 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.234 -0.916 . . . . 0.0 110.869 -179.27 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.628 ' HB3' HD11 ' A' ' 37' ' ' ILE . 7.6 tt -54.12 -42.82 69.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.939 -1.101 . . . . 0.0 110.03 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 69.2 t60 -59.89 -41.14 90.94 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.344 -0.847 . . . . 0.0 110.037 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.851 HD22 ' HA ' ' A' ' 38' ' ' TRP . 2.0 p-10 -99.39 5.59 46.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.352 -0.842 . . . . 0.0 110.121 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.531 ' N ' ' O ' ' A' ' 38' ' ' TRP . 23.7 tp -58.92 -37.19 76.1 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.425 -0.797 . . . . 0.0 110.187 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -56.87 -37.44 78.13 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -56.02 -41.73 75.37 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.198 -1.178 . . . . 0.0 110.177 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -52.64 -37.18 58.03 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.233 -0.917 . . . . 0.0 109.955 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 71.0 mt -59.12 -38.65 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.195 -0.941 . . . . 0.0 109.945 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 70.3 t80 -58.45 -34.99 71.46 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.353 -0.842 . . . . 0.0 110.032 179.638 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.523 ' O ' ' CB ' ' A' ' 49' ' ' THR . 61.2 mm-40 -62.11 147.7 46.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 110.317 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.523 ' CB ' ' O ' ' A' ' 48' ' ' GLU . 2.5 m 71.82 -54.12 0.68 Allowed 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.377 -0.827 . . . . 0.0 110.265 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 18.8 m-30 -72.69 -26.19 61.52 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.285 -0.884 . . . . 0.0 110.556 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.55 99.17 2.5 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.364 0 O-C-N 119.832 -1.981 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ACE . . . . . 0.468 ' O ' ' CB ' ' A' ' 36' ' ' ARG . . . . . . . . 0 C--O 1.215 -0.734 . . . . . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.624 ' CG ' ' NE2' ' A' ' 40' ' ' HIS . 4.9 m-30 -52.91 -42.23 89.07 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 110.255 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.544 ' HD2' ' N ' ' A' ' 34' ' ' PHE . 45.7 Cg_endo -78.17 9.74 2.96 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 123.652 1.343 . . . . 0.0 110.407 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.468 ' CB ' ' O ' ' A' ' 33' ' ' ACE . 45.7 ttp180 -66.9 -40.38 87.71 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.078 -1.014 . . . . 0.0 109.973 179.577 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.72 HD13 ' N ' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -123.08 129.59 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.193 -0.942 . . . . 0.0 110.418 179.621 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.643 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 58.5 p-90 -52.15 -48.71 64.76 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.451 -0.78 . . . . 0.0 111.802 -178.567 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.727 ' HA ' HD13 ' A' ' 42' ' ' LEU . 5.8 tt -48.34 -29.2 3.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.694 -1.254 . . . . 0.0 109.476 -179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.624 ' NE2' ' CG ' ' A' ' 34' ' ' PHE . 85.2 t60 -62.24 -27.11 68.77 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.328 -0.857 . . . . 0.0 109.898 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.529 ' N ' ' ND2' ' A' ' 41' ' ' ASN . 1.2 m120 -68.43 -29.86 68.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.378 -0.826 . . . . 0.0 109.461 179.754 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.727 HD13 ' HA ' ' A' ' 39' ' ' LEU . 7.0 mp -70.58 -30.88 67.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.508 -0.745 . . . . 0.0 109.972 179.704 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -56.45 -37.02 72.58 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 91.2 mt-30 -50.73 -38.4 47.23 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.29 -1.124 . . . . 0.0 110.163 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -59.42 -36.54 76.07 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.255 -0.903 . . . . 0.0 110.053 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.481 HG22 ' HD2' ' A' ' 50' ' ' TYR . 22.0 mm -65.21 -38.35 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.232 -0.918 . . . . 0.0 109.983 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.516 ' O ' ' N ' ' A' ' 51' ' ' GLY . 74.8 t80 -46.41 -49.46 17.99 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.302 -0.874 . . . . 0.0 109.716 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -59.93 -37.02 78.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.394 -0.816 . . . . 0.0 109.957 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 82.5 m -66.72 -38.24 86.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.266 -0.896 . . . . 0.0 110.034 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 0.481 ' HD2' HG22 ' A' ' 46' ' ' ILE . 97.5 m-85 -107.19 13.62 27.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.254 -0.904 . . . . 0.0 110.206 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 72.86 -94.2 0.68 Allowed Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.32 0 O-C-N 119.823 -1.986 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.775 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.507 ' O ' HG12 ' A' ' 37' ' ' ILE . 7.7 m-85 -62.8 126.64 89.08 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.225 -0.922 . . . . 0.0 110.109 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.585 ' HA ' HD12 ' A' ' 39' ' ' LEU . 47.1 Cg_endo -62.85 -9.23 15.76 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 123.945 1.497 . . . . 0.0 110.429 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 37.4 ttp85 -72.81 -24.85 60.96 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.215 -0.928 . . . . 0.0 110.784 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.785 HD11 ' HG ' ' A' ' 39' ' ' LEU . 1.3 pp -68.66 -139.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.038 -1.039 . . . . 0.0 110.218 -179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.742 ' CD1' HD12 ' A' ' 37' ' ' ILE . 46.2 p-90 -66.04 -10.0 35.88 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.661 -1.275 . . . . 0.0 110.4 -179.134 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.785 ' HG ' HD11 ' A' ' 37' ' ' ILE . 37.5 mt -63.53 -24.75 67.94 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.916 -1.115 . . . . 0.0 108.03 177.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 54.7 t-80 -64.37 -28.98 70.06 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.721 -0.612 . . . . 0.0 109.757 179.632 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -60.51 -35.12 75.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.308 -0.87 . . . . 0.0 109.763 179.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.675 HD12 ' N ' ' A' ' 42' ' ' LEU . 7.7 mp -69.47 -38.38 77.7 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.39 -0.819 . . . . 0.0 109.898 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -55.72 -34.63 61.04 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -59.38 -36.52 75.94 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.172 -1.193 . . . . 0.0 110.552 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.415 ' ND1' ' HA ' ' A' ' 42' ' ' LEU . 78.4 m80 -53.96 -40.47 66.87 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.171 -0.956 . . . . 0.0 110.237 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 95.2 mt -61.2 -37.61 77.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.205 -0.935 . . . . 0.0 110.367 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.475 ' O ' ' N ' ' A' ' 51' ' ' GLY . 71.6 t80 -53.72 -46.76 70.92 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.144 -0.972 . . . . 0.0 110.065 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -56.61 -40.69 75.75 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.287 -0.883 . . . . 0.0 110.179 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 89.0 m -62.78 -33.96 76.25 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.11 -0.994 . . . . 0.0 110.2 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -109.05 10.41 26.13 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.295 -0.878 . . . . 0.0 110.252 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -122.61 -75.59 0.34 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.351 0 O-C-N 119.874 -1.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.701 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.543 ' HB2' ' CE1' ' A' ' 40' ' ' HIS . 63.0 m-85 -125.75 78.31 69.29 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.289 -0.882 . . . . 0.0 110.318 . . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -77.04 0.92 9.22 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.89 1.469 . . . . 0.0 110.012 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.5 mtm105 -68.94 -23.01 64.1 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.309 -0.869 . . . . 0.0 110.657 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.922 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.3 OUTLIER -125.31 122.37 62.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.12 -0.987 . . . . 0.0 111.449 -179.044 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.762 ' CH2' HD21 ' A' ' 39' ' ' LEU . 59.1 p-90 -52.31 -41.92 63.36 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.579 -0.701 . . . . 0.0 110.285 179.24 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.762 HD21 ' CH2' ' A' ' 38' ' ' TRP . 34.3 mt -48.63 -33.22 9.49 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.88 -1.137 . . . . 0.0 108.595 178.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.922 ' HB2' HG23 ' A' ' 37' ' ' ILE . 78.4 t60 -70.02 -34.99 73.99 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.406 0.622 . . . . 0.0 109.674 179.559 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.603 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 0.8 OUTLIER -77.88 -14.47 59.54 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.39 -0.819 . . . . 0.0 109.414 179.818 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.679 HD11 ' CZ3' ' A' ' 38' ' ' TRP . 20.3 mt -69.72 -34.41 73.84 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.382 -0.824 . . . . 0.0 109.762 179.408 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -62.96 -34.11 89.03 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -57.37 -34.75 69.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.19 -1.182 . . . . 0.0 109.667 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -62.83 -42.02 99.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.379 -0.826 . . . . 0.0 109.979 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.499 HG23 ' HE1' ' A' ' 50' ' ' TYR . 94.6 mt -61.29 -43.24 96.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.264 -0.897 . . . . 0.0 110.325 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -47.81 -42.92 27.26 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.284 -0.885 . . . . 0.0 110.52 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -68.72 -36.46 78.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.229 -0.919 . . . . 0.0 110.413 -179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 99.9 m -60.48 -50.22 74.45 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.239 -0.913 . . . . 0.0 110.489 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' TYR . . . . . 0.499 ' HE1' HG23 ' A' ' 46' ' ' ILE . 70.6 m-85 -72.22 -23.69 61.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.174 -0.954 . . . . 0.0 110.03 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.9 111.59 3.75 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.341 0 O-C-N 119.876 -1.955 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.713 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.58 ' CD1' ' O ' ' A' ' 34' ' ' PHE . 1.3 t80 -59.74 -37.73 53.21 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.166 -0.959 . . . . 0.0 110.371 . . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 34' ' ' PHE . 48.8 Cg_endo -81.46 13.68 2.36 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.698 1.368 . . . . 0.0 110.224 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.8 ttp180 -72.41 -37.63 68.62 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.349 -0.844 . . . . 0.0 110.288 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.756 HG23 ' CB ' ' A' ' 40' ' ' HIS . 0.3 OUTLIER -125.2 114.82 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.278 -0.889 . . . . 0.0 110.44 -179.831 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.71 ' HA ' ' ND2' ' A' ' 41' ' ' ASN . 61.8 p-90 -59.14 -42.08 89.83 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.393 -0.817 . . . . 0.0 110.257 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.834 ' O ' HD23 ' A' ' 39' ' ' LEU . 8.2 tt -54.02 -18.36 3.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.053 -1.029 . . . . 0.0 109.664 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' HIS . . . . . 0.756 ' CB ' HG23 ' A' ' 37' ' ' ILE . 48.1 t-80 -82.59 -13.56 56.33 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.341 -0.849 . . . . 0.0 109.425 179.406 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.71 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 1.8 m-20 -83.31 -26.29 30.74 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.611 HD11 ' HZ3' ' A' ' 38' ' ' TRP . 80.2 mt -64.41 -38.16 90.06 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.478 -0.764 . . . . 0.0 109.157 179.39 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -65.18 -34.99 91.12 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -58.75 -33.72 70.59 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.272 -1.134 . . . . 0.0 110.056 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.44 ' ND1' ' HA ' ' A' ' 42' ' ' LEU . 78.2 m80 -53.1 -39.34 63.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.318 -0.864 . . . . 0.0 109.822 179.768 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.6 mm -58.78 -43.6 88.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.348 -0.845 . . . . 0.0 110.023 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.486 ' O ' ' N ' ' A' ' 51' ' ' GLY . 73.2 t80 -48.87 -46.63 42.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.302 -0.874 . . . . 0.0 110.04 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -64.61 -38.45 91.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 110.107 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 57.2 m -65.27 -36.03 82.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.143 -0.973 . . . . 0.0 110.167 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -110.68 14.96 22.23 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.323 -0.861 . . . . 0.0 110.305 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -110.27 -131.1 5.97 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.343 0 O-C-N 119.874 -1.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.72 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.446 ' O ' HG12 ' A' ' 37' ' ' ILE . 2.6 m-30 -67.03 124.99 90.22 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.269 -0.894 . . . . 0.0 110.367 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.67 ' HA ' HD23 ' A' ' 39' ' ' LEU . 48.5 Cg_endo -53.54 -19.14 13.0 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 124.085 1.571 . . . . 0.0 109.998 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 11.8 tpt180 -52.09 -31.49 30.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.324 -0.86 . . . . 0.0 110.403 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.553 HD12 ' CG ' ' A' ' 38' ' ' TRP . 1.1 pp -59.73 -156.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.076 -1.015 . . . . 0.0 110.312 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.625 ' HZ3' HD12 ' A' ' 42' ' ' LEU . 19.9 p-90 -55.38 -18.61 7.01 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.133 -0.979 . . . . 0.0 110.554 -179.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.67 HD23 ' HA ' ' A' ' 35' ' ' PRO . 25.3 tp -68.03 -15.23 63.51 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.07 -1.019 . . . . 0.0 109.932 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 86.4 t60 -78.97 -40.07 32.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.268 -0.895 . . . . 0.0 110.044 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.549 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 25.8 p30 -67.74 -22.92 65.21 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.281 -0.887 . . . . 0.0 110.275 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.625 HD12 ' HZ3' ' A' ' 38' ' ' TRP . 15.5 mt -69.52 -32.35 71.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 110.216 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -62.17 -31.73 80.03 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.67 -32.9 72.08 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.278 -1.131 . . . . 0.0 110.198 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -58.23 -43.71 87.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.261 -0.899 . . . . 0.0 110.364 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 78.7 mt -55.01 -43.41 69.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.18 -0.95 . . . . 0.0 110.321 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -51.25 -45.16 61.94 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.24 -0.912 . . . . 0.0 110.118 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.6 -36.99 84.52 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.242 -0.911 . . . . 0.0 110.029 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 70.5 m -62.46 -37.03 84.34 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.18 -0.95 . . . . 0.0 110.026 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -106.6 13.59 28.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.869 . . . . 0.0 110.176 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -102.14 -126.04 5.76 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.323 0 O-C-N 119.872 -1.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.744 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.48 ' H ' ' CD2' ' A' ' 40' ' ' HIS . 0.1 OUTLIER -130.95 79.75 70.88 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.252 -0.905 . . . . 0.0 110.056 . . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.15 -8.37 20.02 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.987 1.519 . . . . 0.0 110.489 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -64.53 -25.07 67.82 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.257 -0.902 . . . . 0.0 110.534 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.789 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.6 OUTLIER -121.82 121.26 63.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.185 -0.947 . . . . 0.0 110.314 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.856 ' HZ3' HD22 ' A' ' 42' ' ' LEU . 65.5 p-90 -60.84 -42.4 97.7 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.408 -0.807 . . . . 0.0 110.87 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.599 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 14.8 tp -54.37 -21.95 10.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.931 -1.106 . . . . 0.0 109.73 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.789 ' HB2' HG23 ' A' ' 37' ' ' ILE . 80.8 t60 -75.63 -39.46 57.75 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.439 -0.788 . . . . 0.0 109.672 179.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -104.71 5.51 33.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.261 -0.899 . . . . 0.0 109.67 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.856 HD22 ' HZ3' ' A' ' 38' ' ' TRP . 19.4 tp -63.11 -38.06 89.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.302 -0.874 . . . . 0.0 110.042 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -55.81 -36.71 66.8 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -63.92 -34.33 77.73 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.383 -1.069 . . . . 0.0 109.971 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -58.34 -46.13 86.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.29 -0.881 . . . . 0.0 110.218 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 17.3 mm -56.49 -43.93 79.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.282 -0.886 . . . . 0.0 110.144 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.495 ' O ' ' N ' ' A' ' 51' ' ' GLY . 66.2 t80 -45.58 -46.49 14.26 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.148 -0.97 . . . . 0.0 109.735 179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -61.46 -37.51 83.85 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.417 -0.802 . . . . 0.0 110.038 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 64.4 m -68.59 -32.08 71.73 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.185 -0.947 . . . . 0.0 110.01 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -111.79 15.72 20.77 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.357 -0.839 . . . . 0.0 110.093 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 49.22 47.55 33.89 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.323 0 O-C-N 119.877 -1.955 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.756 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.447 ' O ' HG12 ' A' ' 37' ' ' ILE . 0.3 OUTLIER -123.96 75.27 57.81 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.17 . . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.624 ' HA ' HD23 ' A' ' 39' ' ' LEU . 49.1 Cg_endo -59.73 -16.68 38.6 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 124.015 1.534 . . . . 0.0 110.346 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -56.63 -30.27 63.11 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.37 -0.831 . . . . 0.0 110.495 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.591 HD12 ' CG ' ' A' ' 38' ' ' TRP . 1.1 pp -58.68 -162.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.192 -0.943 . . . . 0.0 110.492 -179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.591 ' CG ' HD12 ' A' ' 37' ' ' ILE . 24.0 p-90 -53.85 -16.68 1.9 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.169 -0.957 . . . . 0.0 110.388 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.787 HD12 HD22 ' A' ' 42' ' ' LEU . 16.5 tp -66.99 -26.53 66.84 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.999 -1.063 . . . . 0.0 109.325 179.24 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.465 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 86.4 t60 -60.85 -31.6 71.04 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.409 -0.807 . . . . 0.0 109.691 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.568 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 18.2 p30 -95.64 -12.89 24.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.4 -0.813 . . . . 0.0 109.736 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.787 HD22 HD12 ' A' ' 39' ' ' LEU . 27.9 tp -45.17 -43.21 9.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.394 -0.816 . . . . 0.0 110.148 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -48.21 -31.19 8.4 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.402 ' HB2' ' O ' ' A' ' 41' ' ' ASN . 94.5 mt-30 -59.48 -34.98 73.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.367 -1.078 . . . . 0.0 109.925 179.818 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -51.48 -44.53 62.49 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.293 -0.879 . . . . 0.0 109.915 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.406 HG23 ' CE2' ' A' ' 50' ' ' TYR . 21.0 mm -55.13 -45.73 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.939 . . . . 0.0 109.999 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.453 ' O ' ' N ' ' A' ' 51' ' ' GLY . 65.6 t80 -50.29 -46.33 55.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.267 -0.896 . . . . 0.0 109.838 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -68.23 -35.7 78.34 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.378 -0.826 . . . . 0.0 109.904 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 51.5 m -66.3 -36.18 82.3 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.256 -0.902 . . . . 0.0 109.964 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 0.406 ' CE2' HG23 ' A' ' 46' ' ' ILE . 90.7 m-85 -111.8 14.23 21.05 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.318 -0.864 . . . . 0.0 110.098 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -71.36 132.26 20.61 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.291 0 O-C-N 119.895 -1.944 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.705 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.527 ' HB2' ' CD2' ' A' ' 40' ' ' HIS . 0.4 OUTLIER -124.31 82.57 57.65 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 110.2 . . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.82 -6.58 18.36 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 124.041 1.548 . . . . 0.0 110.138 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 63.0 mtt180 -61.27 -30.89 70.75 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.292 -0.88 . . . . 0.0 110.476 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.854 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.7 OUTLIER -124.14 125.59 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.055 -1.028 . . . . 0.0 110.846 -179.611 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.752 ' HZ3' HD22 ' A' ' 42' ' ' LEU . 67.8 p-90 -61.13 -45.06 96.2 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.472 -0.767 . . . . 0.0 110.753 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.726 HD23 ' O ' ' A' ' 39' ' ' LEU . 8.5 tt -50.26 -27.22 5.69 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.01 -1.056 . . . . 0.0 109.628 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.854 ' HB2' HG23 ' A' ' 37' ' ' ILE . 82.0 t60 -70.72 -39.37 73.42 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.451 -0.781 . . . . 0.0 109.557 179.466 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 14.2 p30 -105.17 10.25 33.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.416 -0.802 . . . . 0.0 109.744 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.752 HD22 ' HZ3' ' A' ' 38' ' ' TRP . 24.3 tp -60.78 -35.52 76.65 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.37 -0.831 . . . . 0.0 110.23 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -61.46 -33.76 85.91 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -59.15 -38.41 79.63 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.184 -1.186 . . . . 0.0 110.072 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -56.72 -35.78 68.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.388 -0.82 . . . . 0.0 110.302 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 94.5 mt -61.72 -40.21 86.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.118 -0.989 . . . . 0.0 110.371 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.411 ' O ' ' N ' ' A' ' 51' ' ' GLY . 75.5 t80 -54.27 -46.92 72.79 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.262 -0.899 . . . . 0.0 110.26 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -61.49 -38.06 85.95 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.177 -0.952 . . . . 0.0 110.124 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 54.2 m -61.36 -38.39 86.79 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.321 -0.862 . . . . 0.0 110.141 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -107.61 11.4 28.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.234 -0.916 . . . . 0.0 110.241 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 59.86 -121.22 25.94 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.353 0 O-C-N 119.783 -2.01 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.717 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.586 ' CE2' ' HD2' ' A' ' 36' ' ' ARG . 0.4 OUTLIER -125.12 79.29 65.9 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.237 -0.914 . . . . 0.0 110.219 . . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.03 -6.87 18.19 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.974 1.513 . . . . 0.0 110.224 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.586 ' HD2' ' CE2' ' A' ' 34' ' ' PHE . 95.0 mtt180 -61.14 -32.49 72.2 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.265 -0.897 . . . . 0.0 110.345 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.853 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.5 OUTLIER -122.8 124.32 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.223 -0.923 . . . . 0.0 110.308 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.843 ' HZ3' HD22 ' A' ' 42' ' ' LEU . 63.5 p-90 -60.96 -41.78 97.0 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.364 -0.835 . . . . 0.0 110.989 -179.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.625 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 15.6 tp -54.1 -24.19 16.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.946 -1.096 . . . . 0.0 109.493 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.853 ' HB2' HG23 ' A' ' 37' ' ' ILE . 80.0 t60 -72.27 -47.09 52.77 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.575 -0.703 . . . . 0.0 109.687 179.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 11.1 p30 -99.83 8.09 44.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.326 -0.859 . . . . 0.0 109.833 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.843 HD22 ' HZ3' ' A' ' 38' ' ' TRP . 31.0 tp -54.36 -40.11 67.8 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.376 -0.827 . . . . 0.0 110.01 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -53.61 -37.58 56.82 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.069 -1.612 . . . . 0.0 109.069 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -61.8 -34.48 75.98 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 0.0 109.974 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -54.5 -43.57 71.95 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.235 -0.916 . . . . 0.0 109.888 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 mm -61.16 -37.96 78.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.9 . . . . 0.0 109.974 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 51' ' ' GLY . 64.4 t80 -46.88 -47.85 21.26 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.153 -0.967 . . . . 0.0 109.761 179.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -64.4 -37.8 88.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.361 -0.837 . . . . 0.0 109.978 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 58.9 m -63.76 -35.02 79.2 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.233 -0.917 . . . . 0.0 110.103 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -110.9 14.54 22.08 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.345 -0.847 . . . . 0.0 110.091 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 59.54 -160.59 18.11 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.339 0 O-C-N 119.849 -1.971 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.726 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -122.32 80.55 45.27 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.247 -0.908 . . . . 0.0 110.097 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -63.7 -16.67 56.1 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 124.005 1.529 . . . . 0.0 110.354 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 37.1 ttt180 -58.33 -35.16 71.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.357 -0.839 . . . . 0.0 110.294 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 1.5 pp -71.53 -3.01 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.233 -0.917 . . . . 0.0 110.396 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 39' ' ' LEU . 4.0 m95 -104.91 159.44 15.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.238 -0.914 . . . . 0.0 110.173 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.506 ' HB2' ' O ' ' A' ' 38' ' ' TRP . 17.6 mt 69.11 -50.72 0.6 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.459 -0.776 . . . . 0.0 110.999 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -61.7 -45.3 94.55 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.967 -1.083 . . . . 0.0 110.361 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -71.45 -33.25 69.19 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.242 -0.911 . . . . 0.0 110.418 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 56.3 mt -69.67 -25.17 63.77 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.265 -0.897 . . . . 0.0 109.992 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -60.18 -31.6 73.74 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -60.27 -35.26 75.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.233 -1.157 . . . . 0.0 109.993 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -52.94 -39.29 62.76 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.313 -0.867 . . . . 0.0 109.948 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.014 HG23 ' CE1' ' A' ' 50' ' ' TYR . 91.1 mt -59.01 -46.77 91.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.234 -0.916 . . . . 0.0 110.014 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.415 ' C ' ' O ' ' A' ' 46' ' ' ILE . 75.9 t80 -42.53 -52.16 4.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.436 -0.79 . . . . 0.0 109.797 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -59.83 -43.88 94.34 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 48.1 m -61.37 -40.02 92.79 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.359 -0.838 . . . . 0.0 109.601 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 1.014 ' CE1' HG23 ' A' ' 46' ' ' ILE . 29.5 p90 -174.87 98.94 0.08 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.383 -0.823 . . . . 0.0 110.085 179.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.5 103.99 2.23 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.352 0 O-C-N 119.874 -1.956 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.731 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.607 ' HB2' ' CD2' ' A' ' 40' ' ' HIS . 22.5 m-85 -127.38 80.02 72.39 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.238 -0.914 . . . . 0.0 110.164 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -66.08 -8.12 19.17 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 O-C-N 123.956 1.503 . . . . 0.0 110.38 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 82.2 mtm180 -66.1 -26.34 67.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.267 -0.896 . . . . 0.0 110.624 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.783 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.3 OUTLIER -123.9 116.76 48.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.052 -1.03 . . . . 0.0 110.699 -179.532 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.725 ' CH2' HD12 ' A' ' 39' ' ' LEU . 55.3 p-90 -56.47 -41.07 75.94 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.432 -0.792 . . . . 0.0 110.733 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.725 HD12 ' CH2' ' A' ' 38' ' ' TRP . 0.7 OUTLIER -61.82 -12.75 18.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.18 -0.95 . . . . 0.0 110.757 -179.246 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.783 ' HB2' HG23 ' A' ' 37' ' ' ILE . 82.4 t60 -75.66 -24.75 56.39 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.049 -1.032 . . . . 0.0 109.942 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.591 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 7.2 m-80 -78.47 -17.73 55.87 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.296 -0.877 . . . . 0.0 109.08 179.465 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.724 HD13 ' HA ' ' A' ' 39' ' ' LEU . 9.2 mp -72.57 -32.92 66.4 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.475 ' O ' ' HB ' ' A' ' 46' ' ' ILE . . . -56.3 -42.42 88.72 Favored Glycine 0 N--CA 1.487 2.082 0 N-CA-C 109.07 -1.612 . . . . 0.0 109.07 179.394 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -49.88 -40.07 41.52 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -1.141 . . . . 0.0 109.552 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 82.9 t60 -53.51 -35.39 60.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.232 -0.918 . . . . 0.0 109.452 179.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.836 HG22 ' CE1' ' A' ' 50' ' ' TYR . 95.6 mt -62.83 -43.45 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.337 -0.852 . . . . 0.0 109.355 179.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.56 ' HA ' ' CE1' ' A' ' 50' ' ' TYR . 71.5 t80 -43.18 -46.89 6.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.37 -0.831 . . . . 0.0 109.558 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -66.21 -30.59 71.08 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.337 -0.852 . . . . 0.0 109.796 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.48 ' HB ' ' O ' ' A' ' 46' ' ' ILE . 88.3 m -63.19 -45.54 91.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.25 -0.906 . . . . 0.0 109.886 179.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 0.836 ' CE1' HG22 ' A' ' 46' ' ' ILE . 41.8 p90 -116.99 25.87 10.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.279 -0.888 . . . . 0.0 110.132 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 55.97 -165.18 4.41 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.324 0 O-C-N 119.857 -1.966 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.769 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.565 ' HB2' ' CD2' ' A' ' 40' ' ' HIS . 8.4 m-85 -122.8 84.2 49.55 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.295 -0.878 . . . . 0.0 110.216 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -66.66 -8.39 20.99 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.989 1.521 . . . . 0.0 110.183 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 54.2 mtt85 -58.9 -33.57 70.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.428 -0.795 . . . . 0.0 110.857 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.938 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.2 OUTLIER -127.01 114.12 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.014 -1.054 . . . . 0.0 110.74 -179.45 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.652 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 41.6 p-90 -48.99 -38.71 24.07 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.573 -0.704 . . . . 0.0 110.576 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.652 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 9.2 tt -58.91 -27.9 65.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.257 -0.902 . . . . 0.0 110.08 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.938 ' HB2' HG23 ' A' ' 37' ' ' ILE . 54.7 t-80 -65.19 -35.54 81.38 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.328 -0.858 . . . . 0.0 110.115 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.432 ' ND2' ' H ' ' A' ' 41' ' ' ASN . 4.6 m-80 -79.4 -17.11 55.05 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.137 179.529 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.409 HD12 ' HA ' ' A' ' 42' ' ' LEU . 18.2 tp -74.39 -24.51 59.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.484 -0.76 . . . . 0.0 109.569 179.214 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -69.32 -29.43 71.87 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.04 -1.624 . . . . 0.0 109.04 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -58.63 -30.52 67.34 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.413 -1.051 . . . . 0.0 109.795 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -60.32 -38.66 84.41 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.407 -0.808 . . . . 0.0 110.373 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 22.9 mm -62.14 -37.2 77.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.123 -0.985 . . . . 0.0 110.306 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.474 ' O ' ' N ' ' A' ' 51' ' ' GLY . 75.0 t80 -54.15 -46.74 72.35 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.188 -0.945 . . . . 0.0 110.171 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -66.45 -38.01 86.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.205 -0.934 . . . . 0.0 110.39 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.9 m -65.21 -38.82 91.64 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.177 -0.952 . . . . 0.0 110.227 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -111.27 17.62 20.06 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.279 -0.888 . . . . 0.0 110.135 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -127.6 -108.54 1.49 Allowed Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.337 0 O-C-N 119.903 -1.939 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.759 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.817 ' O ' HG22 ' A' ' 37' ' ' ILE . 2.4 m-85 -124.7 79.23 63.35 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.26 -0.9 . . . . 0.0 110.156 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -55.71 -21.51 32.39 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.934 1.492 . . . . 0.0 110.468 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.484 ' O ' ' HB3' ' A' ' 40' ' ' HIS . 63.3 mtt180 -56.99 -39.74 75.26 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.207 -0.933 . . . . 0.0 110.484 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.998 HD13 ' O ' ' A' ' 37' ' ' ILE . 0.0 OUTLIER -57.28 -28.55 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.22 -0.925 . . . . 0.0 110.218 -179.753 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.608 ' HZ3' HD13 ' A' ' 42' ' ' LEU . 17.3 m95 -98.29 146.24 25.86 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.172 -0.955 . . . . 0.0 110.838 -179.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.539 ' HB2' ' O ' ' A' ' 38' ' ' TRP . 28.6 mt 72.49 -44.72 0.6 Allowed 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.85 -0.531 . . . . 0.0 111.171 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.484 ' HB3' ' O ' ' A' ' 36' ' ' ARG . 58.1 t-80 -58.96 -40.44 84.73 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.677 -1.264 . . . . 0.0 110.207 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.474 ' HB2' ' OE1' ' A' ' 44' ' ' GLN . 47.9 p-10 -123.49 14.35 9.53 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.179 -0.951 . . . . 0.0 110.189 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.608 HD13 ' HZ3' ' A' ' 38' ' ' TRP . 13.6 tp -59.83 -29.66 68.41 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.25 -0.906 . . . . 0.0 110.337 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -60.55 -26.74 64.97 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.474 ' OE1' ' HB2' ' A' ' 41' ' ' ASN . 94.2 mt-30 -71.25 -22.95 61.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.314 -1.11 . . . . 0.0 110.231 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -66.26 -46.09 78.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.324 -0.86 . . . . 0.0 110.563 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.45 ' O ' ' N ' ' A' ' 50' ' ' TYR . 17.8 pt -76.97 -10.61 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.21 -0.932 . . . . 0.0 110.539 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.505 ' C ' ' CD1' ' A' ' 47' ' ' TYR . 6.8 t80 -62.45 -49.24 76.24 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.14 -0.975 . . . . 0.0 110.22 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -56.82 -33.9 67.19 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.149 -0.969 . . . . 0.0 110.359 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 69.9 m -101.72 -73.52 0.65 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.328 -0.858 . . . . 0.0 110.707 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 0.45 ' N ' ' O ' ' A' ' 46' ' ' ILE . 93.1 m-85 -65.22 -33.66 76.53 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.271 -0.893 . . . . 0.0 110.454 -179.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 47' ' ' TYR . . . 77.95 41.13 19.26 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.317 0 O-C-N 119.858 -1.966 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.723 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.603 ' HB2' ' CD2' ' A' ' 40' ' ' HIS . 1.6 m-85 -122.77 83.2 49.13 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.314 -0.866 . . . . 0.0 110.201 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -71.19 -4.46 14.96 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.021 1.537 . . . . 0.0 110.128 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.448 ' CZ ' ' CE2' ' A' ' 34' ' ' PHE . 57.0 mtm180 -66.7 -26.95 67.27 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.304 -0.872 . . . . 0.0 110.582 -179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.789 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.5 OUTLIER -122.97 119.39 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.035 -1.041 . . . . 0.0 110.757 -179.697 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.643 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 54.0 p-90 -56.99 -42.43 80.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.437 -0.79 . . . . 0.0 110.561 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.643 ' N ' ' CD2' ' A' ' 38' ' ' TRP . 16.8 tp -51.62 -29.5 17.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.072 -1.017 . . . . 0.0 109.367 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.789 ' HB2' HG23 ' A' ' 37' ' ' ILE . 70.1 t60 -75.18 -44.22 47.82 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.519 -0.738 . . . . 0.0 109.186 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -79.82 -11.32 59.83 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.345 -0.847 . . . . 0.0 109.316 179.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.515 HD23 ' HZ3' ' A' ' 38' ' ' TRP . 18.9 tp -75.01 -28.11 60.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.419 -0.801 . . . . 0.0 109.801 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -65.14 -31.7 81.58 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -60.72 -35.59 76.73 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.471 -1.017 . . . . 0.0 109.408 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -59.26 -43.19 92.5 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.393 -0.817 . . . . 0.0 109.742 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 87.2 mt -54.74 -47.3 74.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.316 -0.865 . . . . 0.0 110.079 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 71.0 t80 -46.37 -43.88 16.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.237 -0.914 . . . . 0.0 110.077 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 74.7 mm-40 -64.13 -38.16 90.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.332 -0.855 . . . . 0.0 110.073 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 84.8 m -61.02 -49.09 78.8 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.254 -0.904 . . . . 0.0 110.245 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 0.485 ' O ' ' N ' ' A' ' 52' ' ' NH2 . 68.4 m-85 -74.54 -22.81 58.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 110.106 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 62.8 -75.59 0.03 OUTLIER Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . 0.485 ' N ' ' O ' ' A' ' 50' ' ' TYR . . . . . . . . 0 C--N 1.306 -1.32 0 O-C-N 119.919 -1.93 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.74 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.51 ' O ' ' CG1' ' A' ' 37' ' ' ILE . 20.2 m-85 -126.12 72.14 70.59 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.199 -0.938 . . . . 0.0 110.312 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.572 ' CB ' HD23 ' A' ' 39' ' ' LEU . 46.2 Cg_endo -51.21 -19.85 6.93 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 O-C-N 124.01 1.531 . . . . 0.0 110.436 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.405 ' O ' ' O ' ' A' ' 37' ' ' ILE . 81.7 mtt-85 -61.91 -26.83 68.4 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.207 -0.933 . . . . 0.0 110.464 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.566 HD12 ' CG ' ' A' ' 38' ' ' TRP . 1.4 pp -60.61 -151.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.139 -0.976 . . . . 0.0 110.538 -179.405 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.566 ' CG ' HD12 ' A' ' 37' ' ' ILE . 12.7 p-90 -57.29 -22.99 45.54 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.917 -1.114 . . . . 0.0 110.932 -178.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.572 HD23 ' CB ' ' A' ' 35' ' ' PRO . 18.8 tp -54.91 -28.87 54.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.804 -1.185 . . . . 0.0 108.632 179.081 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -62.85 -27.52 69.4 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 178.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.45 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 8.1 m-20 -58.26 -45.72 87.32 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.386 -0.821 . . . . 0.0 109.271 179.207 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.447 HD11 ' HZ3' ' A' ' 38' ' ' TRP . 46.5 mt -56.37 -40.33 74.38 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.424 -0.798 . . . . 0.0 109.541 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -52.29 -27.97 25.84 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.45 ' HB2' ' O ' ' A' ' 41' ' ' ASN . 95.3 mt-30 -59.1 -36.2 74.73 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.256 -1.143 . . . . 0.0 110.112 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -55.08 -43.41 73.91 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.275 -0.891 . . . . 0.0 110.448 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 93.8 mt -60.51 -40.91 85.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.234 -0.916 . . . . 0.0 110.408 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 63.5 t80 -49.63 -38.48 32.3 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.172 -0.955 . . . . 0.0 110.28 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -63.79 -34.07 77.08 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.265 -0.897 . . . . 0.0 110.358 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.49 ' OG1' ' CD1' ' A' ' 50' ' ' TYR . 7.1 p -69.67 -47.04 64.7 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.195 -0.941 . . . . 0.0 110.014 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 0.49 ' CD1' ' OG1' ' A' ' 49' ' ' THR . 71.8 m-85 -76.39 -20.8 56.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.221 -0.924 . . . . 0.0 109.923 179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.67 -12.86 62.53 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.31 0 O-C-N 119.937 -1.919 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.782 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.634 ' CE2' ' NE2' ' A' ' 40' ' ' HIS . 1.1 t80 -125.39 81.94 63.41 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.294 -0.879 . . . . 0.0 110.29 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.645 ' O ' HG23 ' A' ' 37' ' ' ILE . 46.9 Cg_endo -71.55 -4.16 14.48 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.049 1.552 . . . . 0.0 109.62 179.227 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.465 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 65.1 mtt180 57.47 36.18 26.72 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.382 -0.824 . . . . 0.0 110.011 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.89 HD11 ' HB3' ' A' ' 39' ' ' LEU . 1.9 pp -123.75 174.07 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.524 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 1.109 ' CH2' HD12 ' A' ' 39' ' ' LEU . 56.9 p-90 -56.51 -47.7 78.75 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.331 -0.855 . . . . 0.0 111.947 -178.338 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.109 HD12 ' CH2' ' A' ' 38' ' ' TRP . 0.5 OUTLIER -51.53 -37.29 48.7 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 120.622 -1.299 . . . . 0.0 110.31 -179.741 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.634 ' NE2' ' CE2' ' A' ' 34' ' ' PHE . 77.1 t60 -51.61 -37.41 49.9 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.943 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.417 ' ND2' ' H ' ' A' ' 41' ' ' ASN . 6.1 m-80 -78.64 -23.07 46.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.18 -0.95 . . . . 0.0 109.71 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.402 ' HB3' ' O ' ' A' ' 39' ' ' LEU . 30.2 tp -62.17 -30.9 71.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.443 -0.786 . . . . 0.0 109.964 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -60.42 -30.52 71.67 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -59.04 -34.45 71.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.289 -1.124 . . . . 0.0 110.083 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -59.85 -40.54 88.93 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -0.909 . . . . 0.0 110.302 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 84.8 mt -58.29 -40.49 78.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.251 -0.905 . . . . 0.0 110.273 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 70.7 t80 -52.75 -46.09 67.34 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.213 -0.929 . . . . 0.0 110.173 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.17 -34.54 78.62 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.238 -0.914 . . . . 0.0 110.292 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 53.3 m -62.41 -38.26 89.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.158 -0.964 . . . . 0.0 110.165 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.21 13.49 28.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 110.175 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 51.4 94.15 0.01 OUTLIER Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.358 0 O-C-N 119.823 -1.987 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.789 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.6 ' CD2' ' O ' ' A' ' 34' ' ' PHE . 18.6 p90 -132.54 76.95 70.85 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.219 -0.926 . . . . 0.0 110.305 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.507 ' O ' ' HB2' ' A' ' 36' ' ' ARG . 46.6 Cg_endo -40.65 -29.95 0.47 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.791 1.416 . . . . 0.0 110.08 179.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.507 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 15.5 ttt180 171.67 92.36 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.647 -0.658 . . . . 0.0 109.702 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.689 HD12 ' H ' ' A' ' 39' ' ' LEU . 1.1 pp -102.77 -179.04 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.253 -0.904 . . . . 0.0 110.432 -179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.704 ' CH2' HD13 ' A' ' 39' ' ' LEU . 62.5 p-90 -63.8 -47.22 81.76 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.319 -0.863 . . . . 0.0 111.768 -178.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.704 HD13 ' CH2' ' A' ' 38' ' ' TRP . 11.3 tp -61.0 -25.3 66.79 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.6 -1.313 . . . . 0.0 110.326 -179.509 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.463 ' HB2' HG13 ' A' ' 37' ' ' ILE . 80.6 t60 -67.64 -42.72 81.81 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.091 -1.006 . . . . 0.0 109.729 179.629 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 37' ' ' ILE . 9.8 p30 -100.92 8.99 42.82 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.224 -0.923 . . . . 0.0 109.728 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.685 HD22 HD12 ' A' ' 39' ' ' LEU . 8.6 tp -61.08 -30.08 70.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.878 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -63.07 -31.74 81.74 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -62.27 -38.31 88.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -1.166 . . . . 0.0 110.098 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 66.7 m170 -53.97 -39.82 66.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.258 -0.901 . . . . 0.0 110.358 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 96.8 mt -57.13 -46.21 84.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.228 -0.92 . . . . 0.0 110.186 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 73.3 t80 -50.97 -38.37 50.43 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 0.0 110.402 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 52' ' ' NH2 . 95.9 mt-10 -65.21 -32.08 73.57 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.093 -1.005 . . . . 0.0 110.305 -179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.528 ' OG1' ' CD1' ' A' ' 50' ' ' TYR . 6.8 p -72.22 -50.18 29.47 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.322 -0.861 . . . . 0.0 110.163 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 0.528 ' CD1' ' OG1' ' A' ' 49' ' ' THR . 77.6 m-85 -74.02 -24.03 59.5 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.265 -0.897 . . . . 0.0 110.133 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -97.5 -57.99 1.03 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . 0.441 ' N ' ' O ' ' A' ' 48' ' ' GLU . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.921 -1.929 . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.213 -0.822 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.632 ' CE1' ' NE2' ' A' ' 40' ' ' HIS . 0.2 OUTLIER -126.82 77.87 74.04 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.252 -0.905 . . . . 0.0 110.409 . . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.482 ' O ' HG23 ' A' ' 37' ' ' ILE . 46.2 Cg_endo -68.98 -6.3 17.86 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 124.034 1.544 . . . . 0.0 109.5 179.022 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.465 ' HB2' ' O ' ' A' ' 35' ' ' PRO . 79.9 mtt-85 57.87 38.33 27.1 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.39 -0.819 . . . . 0.0 110.164 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.746 HD11 ' HB3' ' A' ' 39' ' ' LEU . 1.3 pp -115.9 174.53 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.443 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.645 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 60.8 p-90 -59.28 -46.72 87.77 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.22 -0.925 . . . . 0.0 111.725 -178.54 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.746 ' HB3' HD11 ' A' ' 37' ' ' ILE . 3.5 tt -54.8 -40.94 69.99 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.81 -1.181 . . . . 0.0 110.261 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.632 ' NE2' ' CE1' ' A' ' 34' ' ' PHE . 72.3 t60 -49.17 -40.44 33.09 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.066 -1.021 . . . . 0.0 109.663 179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.516 ' ND2' ' O ' ' A' ' 37' ' ' ILE . 5.1 m-80 -78.07 -24.43 47.67 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.364 -0.835 . . . . 0.0 109.476 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.616 HD22 ' HZ3' ' A' ' 38' ' ' TRP . 28.9 tp -69.52 -30.38 68.21 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.478 -0.764 . . . . 0.0 109.699 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -65.91 -27.83 73.13 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -60.17 -33.37 72.11 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.322 -1.105 . . . . 0.0 109.831 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -53.47 -48.74 68.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.322 -0.861 . . . . 0.0 110.042 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 89.9 mt -50.68 -46.01 27.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.345 -0.847 . . . . 0.0 110.191 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 70.5 t80 -48.44 -40.83 27.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.208 -0.932 . . . . 0.0 110.146 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.51 -40.65 93.24 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.273 -0.892 . . . . 0.0 110.031 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 94.4 m -60.91 -48.88 79.8 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.287 -0.883 . . . . 0.0 110.22 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -72.75 -24.24 60.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.331 -0.856 . . . . 0.0 110.143 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 50.79 -104.36 0.13 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.364 0 O-C-N 119.866 -1.961 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.746 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.524 ' O ' HG12 ' A' ' 37' ' ' ILE . 21.5 m-85 -119.93 87.12 37.79 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.208 -0.933 . . . . 0.0 110.122 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.525 ' HA ' ' HB2' ' A' ' 39' ' ' LEU . 45.4 Cg_endo -61.91 -10.46 17.54 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.978 1.515 . . . . 0.0 110.539 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 13.4 ttm180 -71.18 -20.69 62.25 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.281 -0.887 . . . . 0.0 111.036 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.882 HD11 ' CD1' ' A' ' 39' ' ' LEU . 1.1 pp -73.47 -131.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 120.834 -1.167 . . . . 0.0 110.053 -179.794 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.778 ' CD1' HD12 ' A' ' 37' ' ' ILE . 12.3 p-90 -69.54 -16.83 63.51 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.574 -1.329 . . . . 0.0 110.661 -179.282 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.882 ' CD1' HD11 ' A' ' 37' ' ' ILE . 1.0 OUTLIER -61.18 -30.47 70.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.991 -1.068 . . . . 0.0 109.353 178.923 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -62.53 -38.76 91.21 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.475 -0.766 . . . . 0.0 110.13 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.561 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 24.8 p30 -85.43 -17.95 35.08 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.229 -0.92 . . . . 0.0 110.19 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.492 ' N ' ' OD1' ' A' ' 41' ' ' ASN . 29.4 tp -43.95 -46.08 8.03 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.222 -0.923 . . . . 0.0 109.973 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.703 ' O ' HG22 ' A' ' 46' ' ' ILE . . . -49.41 -34.16 18.41 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.45 ' HB2' ' O ' ' A' ' 41' ' ' ASN . 95.3 mt-30 -59.27 -32.52 70.09 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.125 -1.22 . . . . 0.0 110.145 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -53.58 -44.43 69.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.346 -0.846 . . . . 0.0 109.999 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.703 HG22 ' O ' ' A' ' 43' ' ' GLY . 7.7 tt -63.63 -33.42 61.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -0.883 . . . . 0.0 110.03 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 60.7 t80 -45.08 -51.6 10.0 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.966 . . . . 0.0 109.332 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -50.13 -44.75 52.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.415 -0.803 . . . . 0.0 109.759 179.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 89.5 m -67.35 -33.81 76.02 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.351 -0.843 . . . . 0.0 110.196 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 0.574 ' CE1' HG12 ' A' ' 46' ' ' ILE . 13.9 m-30 -71.75 -24.8 61.83 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.279 -0.888 . . . . 0.0 109.801 179.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.62 7.84 86.89 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.367 0 O-C-N 119.905 -1.938 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.7 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.647 ' CG ' ' O ' ' A' ' 34' ' ' PHE . 20.0 p90 -122.1 105.81 36.82 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.156 -0.965 . . . . 0.0 110.299 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.575 ' O ' ' CG ' ' A' ' 36' ' ' ARG . 44.1 Cg_endo -67.49 -40.03 11.3 Favored 'Trans proline' 0 C--N 1.3 -1.986 0 O-C-N 123.775 1.408 . . . . 0.0 109.284 179.448 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.575 ' CG ' ' O ' ' A' ' 35' ' ' PRO . 43.2 mtt180 -162.67 85.22 0.55 Allowed 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.669 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.628 HD11 ' HB3' ' A' ' 39' ' ' LEU . 1.3 pt -114.37 163.68 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.842 -1.161 . . . . 0.0 110.417 179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.531 ' O ' ' N ' ' A' ' 42' ' ' LEU . 57.6 p-90 -39.83 -45.34 1.77 Allowed 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.234 -0.916 . . . . 0.0 110.869 -179.27 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.628 ' HB3' HD11 ' A' ' 37' ' ' ILE . 7.6 tt -54.12 -42.82 69.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.939 -1.101 . . . . 0.0 110.03 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 69.2 t60 -59.89 -41.14 90.94 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.344 -0.847 . . . . 0.0 110.037 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.462 ' OD1' ' HA ' ' A' ' 38' ' ' TRP . 3.1 p30 -99.39 5.59 46.32 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.352 -0.842 . . . . 0.0 110.121 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.531 ' N ' ' O ' ' A' ' 38' ' ' TRP . 23.7 tp -58.92 -37.19 76.1 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.425 -0.797 . . . . 0.0 110.187 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -56.87 -37.44 78.13 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -56.02 -41.73 75.37 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.198 -1.178 . . . . 0.0 110.177 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.479 ' CD2' ' HA ' ' A' ' 42' ' ' LEU . 74.2 m-70 -52.64 -37.18 58.03 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.233 -0.917 . . . . 0.0 109.955 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 71.0 mt -59.12 -38.65 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.195 -0.941 . . . . 0.0 109.945 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 70.3 t80 -58.45 -34.99 71.46 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.353 -0.842 . . . . 0.0 110.032 179.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.523 ' O ' ' CB ' ' A' ' 49' ' ' THR . 61.2 mm-40 -62.11 147.7 46.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 110.317 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.523 ' CB ' ' O ' ' A' ' 48' ' ' GLU . 2.5 m 71.82 -54.12 0.68 Allowed 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.377 -0.827 . . . . 0.0 110.265 -179.597 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 18.8 m-30 -72.69 -26.19 61.52 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.285 -0.884 . . . . 0.0 110.556 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -92.55 99.17 2.5 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.364 0 O-C-N 119.832 -1.981 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . 0.468 ' O ' ' CB ' ' A' ' 36' ' ' ARG . . . . . . . . 0 C--O 1.215 -0.734 . . . . . . . . 0.0 . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.624 ' CG ' ' NE2' ' A' ' 40' ' ' HIS . 4.9 m-30 -52.91 -42.23 89.07 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.212 -0.93 . . . . 0.0 110.255 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.544 ' HD2' ' N ' ' A' ' 34' ' ' PHE . 45.7 Cg_endo -78.17 9.74 2.96 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 123.652 1.343 . . . . 0.0 110.407 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.468 ' CB ' ' O ' ' A' ' 33' ' ' ACE . 45.7 ttp180 -66.9 -40.38 87.71 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.078 -1.014 . . . . 0.0 109.973 179.577 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.72 HD13 ' N ' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -123.08 129.59 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.193 -0.942 . . . . 0.0 110.418 179.621 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.643 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 58.5 p-90 -52.15 -48.71 64.76 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.451 -0.78 . . . . 0.0 111.802 -178.567 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.727 ' HA ' HD13 ' A' ' 42' ' ' LEU . 5.8 tt -48.34 -29.2 3.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.694 -1.254 . . . . 0.0 109.476 -179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.624 ' NE2' ' CG ' ' A' ' 34' ' ' PHE . 85.2 t60 -62.24 -27.11 68.77 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.328 -0.857 . . . . 0.0 109.898 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.529 ' N ' ' ND2' ' A' ' 41' ' ' ASN . 1.2 m120 -68.43 -29.86 68.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.378 -0.826 . . . . 0.0 109.461 179.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.727 HD13 ' HA ' ' A' ' 39' ' ' LEU . 7.0 mp -70.58 -30.88 67.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.508 -0.745 . . . . 0.0 109.972 179.704 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -56.45 -37.02 72.58 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 91.2 mt-30 -50.73 -38.4 47.23 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.29 -1.124 . . . . 0.0 110.163 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -59.42 -36.54 76.07 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.255 -0.903 . . . . 0.0 110.053 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.481 HG22 ' HD2' ' A' ' 50' ' ' TYR . 22.0 mm -65.21 -38.35 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.232 -0.918 . . . . 0.0 109.983 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.516 ' O ' ' N ' ' A' ' 51' ' ' GLY . 74.8 t80 -46.41 -49.46 17.99 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.302 -0.874 . . . . 0.0 109.716 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -59.93 -37.02 78.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.394 -0.816 . . . . 0.0 109.957 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 82.5 m -66.72 -38.24 86.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.266 -0.896 . . . . 0.0 110.034 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 0.481 ' HD2' HG22 ' A' ' 46' ' ' ILE . 97.5 m-85 -107.19 13.62 27.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.254 -0.904 . . . . 0.0 110.206 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . 72.86 -94.2 0.68 Allowed Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.32 0 O-C-N 119.823 -1.986 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.775 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.507 ' O ' HG12 ' A' ' 37' ' ' ILE . 7.7 m-85 -62.8 126.64 89.08 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.225 -0.922 . . . . 0.0 110.109 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.585 ' HA ' HD12 ' A' ' 39' ' ' LEU . 47.1 Cg_endo -62.85 -9.23 15.76 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 123.945 1.497 . . . . 0.0 110.429 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 37.4 ttp85 -72.81 -24.85 60.96 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.215 -0.928 . . . . 0.0 110.784 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.785 HD11 ' HG ' ' A' ' 39' ' ' LEU . 1.3 pp -68.66 -139.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.038 -1.039 . . . . 0.0 110.218 -179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.742 ' CD1' HD12 ' A' ' 37' ' ' ILE . 46.2 p-90 -66.04 -10.0 35.88 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.661 -1.275 . . . . 0.0 110.4 -179.134 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.785 ' HG ' HD11 ' A' ' 37' ' ' ILE . 37.5 mt -63.53 -24.75 67.94 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.916 -1.115 . . . . 0.0 108.03 177.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . . . . . . . . . 54.7 t-80 -64.37 -28.98 70.06 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.721 -0.612 . . . . 0.0 109.757 179.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.42 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 18.3 m-20 -60.51 -35.12 75.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.308 -0.87 . . . . 0.0 109.763 179.436 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.675 HD12 ' N ' ' A' ' 42' ' ' LEU . 7.7 mp -69.47 -38.38 77.7 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.39 -0.819 . . . . 0.0 109.898 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -55.72 -34.63 61.04 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -59.38 -36.52 75.94 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.172 -1.193 . . . . 0.0 110.552 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.415 ' ND1' ' HA ' ' A' ' 42' ' ' LEU . 78.4 m80 -53.96 -40.47 66.87 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.171 -0.956 . . . . 0.0 110.237 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 95.2 mt -61.2 -37.61 77.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.205 -0.935 . . . . 0.0 110.367 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.475 ' O ' ' N ' ' A' ' 51' ' ' GLY . 71.6 t80 -53.72 -46.76 70.92 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.144 -0.972 . . . . 0.0 110.065 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -56.61 -40.69 75.75 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.287 -0.883 . . . . 0.0 110.179 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 89.0 m -62.78 -33.96 76.25 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.11 -0.994 . . . . 0.0 110.2 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -109.05 10.41 26.13 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.295 -0.878 . . . . 0.0 110.252 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -122.61 -75.59 0.34 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.351 0 O-C-N 119.874 -1.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.701 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.543 ' HB2' ' CE1' ' A' ' 40' ' ' HIS . 63.0 m-85 -125.75 78.31 69.29 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.289 -0.882 . . . . 0.0 110.318 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -77.04 0.92 9.22 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.89 1.469 . . . . 0.0 110.012 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.5 mtm105 -68.94 -23.01 64.1 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.309 -0.869 . . . . 0.0 110.657 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.922 HG23 ' HB2' ' A' ' 40' ' ' HIS . 0.3 OUTLIER -125.31 122.37 62.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.12 -0.987 . . . . 0.0 111.449 -179.044 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.762 ' CH2' HD21 ' A' ' 39' ' ' LEU . 59.1 p-90 -52.31 -41.92 63.36 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.579 -0.701 . . . . 0.0 110.285 179.24 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.762 HD21 ' CH2' ' A' ' 38' ' ' TRP . 34.3 mt -48.63 -33.22 9.49 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.88 -1.137 . . . . 0.0 108.595 178.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.922 ' HB2' HG23 ' A' ' 37' ' ' ILE . 78.4 t60 -70.02 -34.99 73.99 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.406 0.622 . . . . 0.0 109.674 179.559 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.603 ' ND2' ' HA ' ' A' ' 38' ' ' TRP . 0.8 OUTLIER -77.88 -14.47 59.54 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.39 -0.819 . . . . 0.0 109.414 179.818 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.679 HD11 ' CZ3' ' A' ' 38' ' ' TRP . 20.3 mt -69.72 -34.41 73.84 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.382 -0.824 . . . . 0.0 109.762 179.408 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -62.96 -34.11 89.03 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -57.37 -34.75 69.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.19 -1.182 . . . . 0.0 109.667 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -62.83 -42.02 99.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.379 -0.826 . . . . 0.0 109.979 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.499 HG23 ' HE1' ' A' ' 50' ' ' TYR . 94.6 mt -61.29 -43.24 96.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.264 -0.897 . . . . 0.0 110.325 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -47.81 -42.92 27.26 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.284 -0.885 . . . . 0.0 110.52 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -68.72 -36.46 78.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.229 -0.919 . . . . 0.0 110.413 -179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 99.9 m -60.48 -50.22 74.45 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.239 -0.913 . . . . 0.0 110.489 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . 0.499 ' HE1' HG23 ' A' ' 46' ' ' ILE . 70.6 m-85 -72.22 -23.69 61.28 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.174 -0.954 . . . . 0.0 110.03 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.9 111.59 3.75 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.341 0 O-C-N 119.876 -1.955 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.215 -0.713 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.58 ' CD1' ' O ' ' A' ' 34' ' ' PHE . 1.3 t80 -59.74 -37.73 53.21 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.166 -0.959 . . . . 0.0 110.371 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 34' ' ' PHE . 48.8 Cg_endo -81.46 13.68 2.36 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.698 1.368 . . . . 0.0 110.224 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 45.8 ttp180 -72.41 -37.63 68.62 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.349 -0.844 . . . . 0.0 110.288 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.756 HG23 ' CB ' ' A' ' 40' ' ' HIS . 0.3 OUTLIER -125.2 114.82 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.278 -0.889 . . . . 0.0 110.44 -179.831 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.632 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 61.8 p-90 -59.14 -42.08 89.83 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.393 -0.817 . . . . 0.0 110.257 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.834 ' O ' HD23 ' A' ' 39' ' ' LEU . 8.2 tt -54.02 -18.36 3.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.053 -1.029 . . . . 0.0 109.664 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' HIS . . . . . 0.756 ' CB ' HG23 ' A' ' 37' ' ' ILE . 67.8 t60 -82.59 -13.56 56.33 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.341 -0.849 . . . . 0.0 109.425 179.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.558 ' OD1' ' HA ' ' A' ' 38' ' ' TRP . 0.7 OUTLIER -83.31 -26.29 30.74 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.976 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.611 HD11 ' HZ3' ' A' ' 38' ' ' TRP . 80.2 mt -64.41 -38.16 90.06 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.478 -0.764 . . . . 0.0 109.157 179.39 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -65.18 -34.99 91.12 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -58.75 -33.72 70.59 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.272 -1.134 . . . . 0.0 110.056 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.44 ' ND1' ' HA ' ' A' ' 42' ' ' LEU . 78.2 m80 -53.1 -39.34 63.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.318 -0.864 . . . . 0.0 109.822 179.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.6 mm -58.78 -43.6 88.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.348 -0.845 . . . . 0.0 110.023 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.486 ' O ' ' N ' ' A' ' 51' ' ' GLY . 73.2 t80 -48.87 -46.63 42.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.302 -0.874 . . . . 0.0 110.04 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -64.61 -38.45 91.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 110.107 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 57.2 m -65.27 -36.03 82.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.143 -0.973 . . . . 0.0 110.167 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -110.68 14.96 22.23 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.323 -0.861 . . . . 0.0 110.305 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 47' ' ' TYR . . . -110.27 -131.1 5.97 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.343 0 O-C-N 119.874 -1.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_